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Abstract 
Clostridium difficile is a Gram-positive, spore-forming, toxin producing pathogen 
that has rapidly gained resistance to several broad-spectrum antibiotics. C. 
difficile infection (CDI) is a leading cause of hospital-acquired illness and presents a unique 
challenge to therapeutic development, as it is both caused by and clinically managed with 
antibiotics that indiscriminately kill bacteria present in gut microbiota. As such, identifying 
new drug targets that affect novel pathways is urgently required in order to combat the rise 
of CDI. To address this, we focus on elucidating the caseinolytic protease P (ClpP) system 
in C. difficile, which has emerged as a promising new target for antibacterial development. 
Herein, we describe the biochemical characterization and phenotypic response to loss of 
ClpP1 and ClpP2 in vitro to establish: 1) proteolytic activity and susceptibility to chemo-
activation differ between ClpP1 and ClpP2 and that these two isoforms are capable of 
functioning in an uncoupled fashion. 2) ClpP1 and ClpP2 together are required for 
sporulation and thus are viable drug targets. We conclude this work with our initial 
discovery of a novel ClpP activator, Sclerotiamde, and our work towards the optimization 
of another class of ClpP activators. The work herein describes the uniqueness of the ClpP 
system in C. difficile, opens new avenues of inquiry, and highlights added impact of 
additional detailed structural, genetic, and biological characterization of this system. 
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Chapter 1 
Introduction 
1.1 Clostridium difficile Infection 
Clostridium difficile is a Gram-positive, anaerobic, toxin-producing, spore-forming 
bacteria that causes infection in the lower intestinal tract, capable of producing life-
threatening diarrhea and pseudomembranous colitis.1–5 C. difficile infections (CDI) are the 
predominant cause of nosocomial diarrhea and typically arise due to broad-spectrum 
antibiotic use that eradicate protective intestinal microflora.6–8 The Centers of Disease 
Control (CDC) lists C. difficile as one the top three threats to human health. This pathogen 
caused >29,000 mortalities and produced an estimated $5B in additional healthcare 
expenditures in 2011.3,9 Relapse has increased five to ten-fold over the last decade, 
emphasizing the increased transmission and subsequent recurrence of CDI.10–12 Reports of 
antibiotic resistant C. difficile hospital outbreaks became more common in the early 2000’s, 
as mortality rates rose sharply.13,14 Poor antibiotic stewardship is largely cited as the driving 
force behind C. difficile becoming such a deadly pathogen. Continued evolution has now 
led to hypervirulent strains of C. difficile that have begun to outcompete the previously 
more common less deadly endemic strains.15–17  
Collectively referred to as the “BI/NAP1/027” group, these hypervirulent strains 
produce significantly more toxin than former less virulent strains.14,15,18–23 Gradually, 
hypervirulent strains have largely replaced endemic strains, especially in communal 
settings, suggesting that the increase in virulence is advantageous to the pathogen.24 Some 
hypervirulent strains also demonstrate increased sporulation rates (hypersporulating), 
   
 
 2 
which dramatically increases the number of spores shed in fecal matter and results in more 
efficient transmission of the infection.15,17,18,23,25 Spores are the metabolically dormant 
vessel some Gram-positive organisms produce in response to stress. These spores are able 
to withstand harsh environments for a prolonged time period (some for millions of years)26 
until favorable growth conditions trigger spore germination and outgrowth.27 Harsh 
sterilization approaches (e.g., peroxides, radiation, heat, and chemical fixation) often times 
fail to eradicate spores from surfaces.28–32 In nosocomial settings, spores have been 
reported to germinate after a >6-month desiccation period,33 and in some cases become 
airborne.34 These factors sometimes coalesce and recalcitrant spores can broadly inhabit 
an entire hospital wing, forcing closure.35 Taken together, hypervirulent strains rapidly 
shift between heavy toxin and spore producing phenotypes to cause greater damage to the 
host and ensure future propagation. These features propagate CDI by increasing 
gastrointestinal destruction and inflammation in the host, which induces severe diarrhea, 
and thus provides the vehicle for transmission.  
 
Figure 1.1 The CDI Cycle  
The process of C. difficile infection from hospitalization to clinical outcome. Clinical 
interventions include but are not limited to antibiotic treatment, rehydration and/or fecal 
transplants. Adapted from Hunt and Ballard.20 
 
   
 
 3 
The disease cycle of CDI initiates when spores are ingested via contact with a 
contaminated source, often facilitated by the close quartered nature of healthcare and 
community settings (Figure 1.1).36,37 Once ingested, spores pass into the stomach where 
the acidic environment dissolves the mother cell (the larger body that matures the 
forespore) and releases the enclosed spore. Upon activation of germination sensors, 
outgrowth occurs in the lower gastrointestinal tract where the environment is anoxygenic 
(Figure 1.2).38,39 In an asymptomatic infection, germination is largely inhibited by the low 
concentration of nutrients, and secreted metabolites from commensal bacteria.40,41 Lack of 
a host-defense response may also inhibit germination, as evidence suggests C. difficile 
senses the human antimicrobial peptide LL-37 via the transcriptional regulator ClnR to 
globally regulate toxin production and sporulation.25,42 In this manner, asymptomatic 
carriers shed spores in stool over 1-3 weeks.43 In this transient model of infection C. 
difficile is not considered pathogenic, because host colonic flora has not been disrupted by 
antibiotic intervention.44  
 
Figure 1.2 Stages of CDI Disease Progression  
Shown on the left are the stages of CDI disease progression beginning with (A) the 
ingestion of C. difficile spores. Spores then move from the stomach to the small intestine 
(B) and migrate through the small intestine (C) before germinating in the large intestine 
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(D). Germinating C. difficile spores release toxins in the colon (E) during outgrowth, before 
new spores are made (F), which are shed in fecal matter allowing transmission and/or re-
infection of the host. The image on the right shows the individual stages leading to, and 
during the disease state of CDI. Image was adapted and modified from Breitrück et al.45 
 
In a symptomatic infection, the disease state is proportional to the amount of toxin 
produced and secreted, which will be more severe with a hypervirulent CDI.14,46 Toxin 
production and sporulation are heavily influenced by nutrient availability and carbon 
catabolite repression.47–50 Primarily, oligopeptide transferases (Opp/App) and the 
phosphotransferase system (PTS) uptake nutrients that passively inhibit toxin production 
and/or sporulation, by influencing CcpA and CodY.48,51,52 Both CcpA and CodY are known 
as nutrient sensors and act as global regulatory factors in C. difficile.48,53–55 In the presence 
of guanosine triphosphate (GTP) and branched-chain amino acids (BCAA) CodY binds 
DNA to block expression, suppressing sporulation initiation factors and toxin 
production.54,56,57 Additionally, in the presence of glucose, CcpA suppresses toxin 
production, but the mechanism of toxin downregulation in this case is unclear, as ccpA 
mutants also attenuate toxin production.52 Unlike CodY, which inhibits transcription 
through binding DNA, CcpA is suggested to bind Spo0A and prevent 
phosphorylation/activation to reduce sporulation and suppress toxin production.58 These 
two global regulators often converge to strictly regulate these two critical processes.   
The destruction of the intestinal tissue begins with the glucosylation of Rho proteins 
by toxins TcdA and TcdB.59–62 Glucosylation of host Rho proteins stimulates the immune 
response and triggers inflammation.63,64 Severe diarrhea occurs as a result of tissue damage, 
due to water infiltration of the extracellular space. As tissue turns necrotic, macrophages, 
neutrophils, and macrophils diffuse to the infection site to attack C. difficile, resulting in 
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pseudomembranous colitis (PMC, Figure 1.2).65 Characteristic yellow plaques form on the 
surface of the inflamed tissue, where toxins have begun to erode the intestinal mucosa. If 
clinical intervention is delayed or PMC is left untreated, the illness can progress to toxic 
megacolon.66 Antibiotic treatment in this case warrants discretion, as the bacterial load is 
high and some hypervirulent strains increase toxin production in the presence of 
antibiotics.2,67 In severe cases, the necrotic section of intestine is removed via colectomy 
because the damage is too extensive for recovery.68 C. difficile produces toxins for two 
reasons: 1) limit competition for nutrients by destroying surrounding host-cells, and 2) 
sufficiently induce diarrhea to shed spores and propagate infection in new hosts. 
Both toxin genes, tcdA and tcdB, are located within the PaLoc, which also contains 
tcdR, tcdE, and tcdC.69,70 As C. difficile germinates and approaches stationary growth, 
toxins TcdA and TcdB are produced (Figure 1.3). TcdA (308kDa) and TcdB (270kDa) are 
large clostridial toxins that are responsible for producing the clinical phenotype of CDI. 
tcdR is an RNA sigma factor that promotes PaLoc expression, while tcdE is a bacteriophage 
holin required for toxin secretion.71,72 tcdC is a PaLoc repressor that negatively influences 
PaLoc expression. Each toxin has four domains with specific functions, from the N-
terminus to the C-terminus. The domains are: activity (A), cutting (C), delivery (D), and 
binding (B).47 Domain A on the N-terminus is the glucosyltransferase, the enzymatic 
portion of the toxin that glycosylates Rho proteins. The modification of Rho proteins 
causes the pathogenic effects of C. difficile, and the severity of Rho glycosylation is 
directly proportional to the intensity of the disease state.73 Domain B is comprised of a 
combined repetitive peptides (CROP) motif that is responsible for recognizing and binding 
cell-surface receptors.47 The cutting domain C, is an autoproteolytic domain that is 
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activated when exposed to the cytosol, to cleave the toxin and release the N-terminal 
glucosyltransferase domain A. The toxins share approximately 50% sequence identity, 
with significant differences in the binding domain.  
TcdA binds glycoprotein gp96 in HT29 cells in vitro, and several non-human 
glycan sequences.74,75 Evidence suggests gp96 is largely a cofactor that enhances binding, 
as gp96 expression is not required for TcdA internalization or virulence.76 The required 
extracellular receptor(s) that induce  TcdA internalization remain unknown. Upon receptor 
binding, internalization via endocytosis proceeds in a syndapin-II and dynamin mediated 
fashion.77 TcdB has been shown to bind chondroitin sulfate proteoglycan 4 (CSPG4) and 
the Wnt receptor Frizzled (FZD), both present on the cell surface.78,79 However, TcdB is 
internalized via clathrin mediated endocytosis, which differs from TcdA.80 
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Figure 1.3 Toxin mechanism of action against epithelial cells.  
A) TcdA and TcdB: once internalized, each toxin undergoes the same uptake and release 
process after endosome engulfment. The toxin-receptor complex is enveloped and pinched 
off at the cell surface, forming the endosome. As the pH inside the endosome becomes 
acidified the toxin changes conformation and embeds into the endosomal wall using 
domain B. Once embedded, A and C domains are exposed to the cytosol and inositol 
hexakisphosphate (IP6) activates CPD (domain C) to autoproteolytically cleave, releasing 
GTD (domain A). The glucosyltransferase is then free to glycosylate Rho proteins. B) CdtA 
and CdtB: once expressed, forming a dimer which binds lipoprotein receptor (LSR). 
CdtAB is then internalized, and as the endosome is acidified CdtB will and embed into the 
endosomal wall forming a pore that CdtA will diffuse through. CdtA, an ADP-ribosyl 
transferase, will then bind to uncapped actin to prevent polymerization and cause actin 
filaments to protrude outside the cellular surface. This image was modified and adapted 
from Pamer et al.64 
 
Approximately 5-30% of hypervirulent C. difficile strains produce a third toxin 
known as “CDT” or “binary toxin”.75 CDT is a ADP-ribosyl transferase toxin that primarily 
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affects actin in eukaryotic cells, but the specific function and role of CDT in pathogenesis 
is poorly understood. The CDT locus (CDTloc) is chromosomally distant from the PaLoc, 
encoding cdtA, cdtB, and cdtR.81,82 cdtA and cdtB are arranged in an operon (cdtAB) that is 
constitutively expressed, and combine to form the heterodimeric toxin CDT (Figure 
1.3).82,83 Expression is positively regulated by CdtR, which has also been shown to 
upregulate PaLoc expression.56 CdtA is an ADP-ribosyltransferase that ribosylates 
uncapped actin filaments in eukaryotic cells, while CdtB contains the binding domain and 
aids CdtA entry.83–85 The cell surface receptor for CDT is lipolysis-stimulated lipoprotein 
receptor (LSR), that is primarily involved with low-density lipoprotein 
clearance/apolipoprotein remodeling.86–88 LSR also functions to maintain cellular junctions 
that contribute to cytoskeletal fidelity.75,89 CDT binds LSR and accumulates at the cell 
surface on lipid rafts, and is internalized. On the interior of the acidified endosome, CdtB 
forms a tetradecameric barrel that inserts into the vesicle wall forming a pore.87,90 CDT 
then translocates to the cytosol where cochaperones aid refolding, allowing CdtA to ADP-
ribosylate immature actin.87,91,92 The ribosylated actin is unable to polymerize and forms 
bundles that protrude from the cell surface.85,93 A recent study suggests that protruding 
actin filaments from the host cells aid C. difficile adherence during infection, offering a 
potential role for CDT in pathogenesis.94 CDI caused by a hypervirulent strain that express 
CDT is more likely to have a fatal outcome, further emphasizing the role of CDT in CDI 
severity and infectivity.83  
1.2 Clinical Management of CDI, and Treatments on the Horizon 
The clinical management of CDI is complex. Poor antibiotic stewardship is largely 
responsible for creating multiple-antibiotic resistant C. difficile strains and the inability to 
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effectively treat this pathogen.95 Historically, CDI has been relegated to nosocomial 
settings and primarily occurs in elderly populations, and those with reduced immune 
capacity.96 Over time, CDI has increased in younger populations, and has infiltrated 
communal settings.97–99 To complicate the situation even further, the lack of consensus for 
a specific treatment protocol has diversified antibiotic resistance in C. difficile strains.100–
102 Generally, treatment proceeds over intervals of singular or combinatorial doses of 
vancomycin, fidaxomycin, and metronidazole, until diagnostic testing no longer detects 
TcdA/TcdB.103 Vancomycin and metronidazole share failure rates ranging from 14-27%, 
while fidaxomicin fails during 12% of treatments.104 On average, 22.6% and 11.7% of 
patients will relapse when treated with vancomycin and metronidazole, respectively. In 
comparison, patients treated with Fidaxomicin exhibit less than a 50% likelihood to 
relapse.104 Fecal microbiota transplant (FMT) has showed promising results with a failure 
rate of approximately 8%, but routine clinical application remains to be established.105  
Elegant genomic studies have elucidated specific bacterial taxa that are 
underrepresented in CDI patients, providing further evidence that microflora dysbiosis 
enhances susceptibility to C. difficile.106 Correcting an imbalanced microflora may impart 
protective effects. FMT has gained attention in recent years as a method capable of 
artificially repopulating gut microflora of an infected patient with that from a healthy fecal 
donor. This replacement restores the balance amongst gut microbiota following antibiotic 
therapy.107,108 FMT demonstrates promising initial results in both treating CDI, and 
reducing patient relapse, boasting a success rate of over 90% in clinical trials.109 Similarly, 
diets incorporating prebiotic and probiotic supplements have increased in popularity, as 
connections between our health and specific commensal taxa are discovered. 
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As a spore-former, C. difficile possesses intrinsic resistance to antibiotics that target 
an active metabolic pathway. Spores allow C. difficile to be transmitted and tolerate 
oxygenic environments, therefore sporulation is a key step in the infection cycle. Disabling 
or minimizing sporulation would dramatically reduce the rate of transmission by 
terminating the infection cycle. So far, no drugs have been approved by the U.S. Food and 
Drug Administration (FDA) that target C. difficile sporulation.110,111  
Metronidazole, vancomycin, and fidaxomicin are the most commonly used 
antibiotics to treat CDI (Figure 1.5).102,112 Metronidazole is the preferred first-line drug 
against perceived CDI when a diagnoses has yet to be confirmed113 Metronidazole is a 
small molecule pro-drug that passively diffuses through the cell wall of C. difficile, and 
into the cytoplasm.114,115 Ferredoxin reduces metronidazole to yield the active form, which 
creates a nitroso-free-radical that reacts with DNA.104 This damages DNA and overwhelms 
C. difficile, inducing a DNA damage stress response, which stalls genomic replication and 
ultimately leads to cell death.116,117 Resistance to metronidazole has steadily increased in 
the last 5-10 years, but this drug is still used commonly, as it is selective towards Gram-
positive anaerobes.118 A recent meta-analysis suggests that metronidazole is no longer 
useful in treating CDI for any case, and fidaxomicin should replace it as a first-line 
treatment.119 Though this suggestion is merely an opinion, it suggests that a classically 
employed drug to treat CDI may soon be out of practice.   
Vancomycin is a broad-spectrum hydrophobic macrocyclic peptide that inhibits 
cell wall synthesis in Gram-positive bacteria (Figure 1.5).120 Specifically, vancomycin 
binds a precursor component of the cell wall, the dipeptide D-Ala-D-Ala, preventing 
peptidoglycan cross-linkage.121 This perforates the cell wall, releasing intracellular 
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contents into the extracellular space, causing cell death. C. difficile is highly susceptible to 
vancomycin (MIC = 1-2 µg/mL) with only a few resistant mutants known to exist.104,122 
Vancomycin resistant phenotypes that are observed, typically modify the terminal 
dipeptide residues that vancomycin binds which blocks the mechanism of action.121 
Vancomycin reduces sporulation more than metronidazole and maintains a long-term 
asymptomatic response.119 
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Figure 1.4 – A list of common antibiotics prescribed to treat CDI.  
A) Vancomycin is a cell permeabilizer of Gram-positive bacteria, which kills bacteria by 
inhibiting cell wall synthesis, causing pores to form across the cell surface. B) Fidaxomicin 
is a narrow-spectrum antibiotic that kills Gram-positive anaerobic bacteria by inhibiting 
RNAP, which stalls transcription at the promoter region of a gene being expressed. C) 
Metronidazole has broad-spectrum activity across Gram-positive bacteria, which works by 
damaging chromosomal DNA to overwhelm the bacteria and halt replication. 
 
Fidaxomicin is a macrolide antibacterial that exhibits narrow-spectrum selectivity 
against C. difficile and thus exhibits minimal threat to commensal flora (Figure 1.4).123–127 
Furthermore, fidaxomicin’s unique mechanism of action has prolonged its clinical use, as 
only one resistant mutant has been reported.122 Fidaxomicin kills C. difficile by inhibiting 
RNA polymerase (RNAP) during transcription initiation, locking the RNAP holocomplex 
to the DNA prior to strand separation.128 This sequesters the transcription complex to the 
promoter region of the gene, blocking future expression and prohibiting RNAP from 
expressing other genes. The cost-effectiveness of fidaxomicin is significantly higher than 
vancomycin or metronidazole.119 The primary drawback of treating CDI with fidaxomicin 
is that almost a third of patients (29%) exhibit no long-term curative effect. This means 
that a third of patients will have a significantly higher risk of recurrent CDI, experience an 
extended disease state, and provide the necessary vehicle for the disease to continue to 
propogate.124 
Alternative therapies that employ non-small molecule-based strategies are under 
development or have entered clinical trials and represent a significant departure from the 
status quo. For example, monoclonal-antibodies that guide the host-immune response to 
clear CDI has demonstrated proof-of-concept.129 Vaccination with inactivated toxin to 
elicit a protective immune response and abrogate virulence by inhibiting toxin activity has 
also been demonstrated in vitro.130–133 Phage therapy is  being revisited as a potential 
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alternative treatment, despite numerous clinical hurdles.134 Most alternative therapies 
attempt to mitigate virulence rather than destroy C. difficile, and shape an immune 
response. This removes the primary drawback of using antibacterials that contribute to gut 
dysbiosis and CDI recurrence. Though exciting, alternative therapies face an uphill battle, 
as the new approaches will be expected to not only exhibit efficacy but also be void of 
problems facing established drugs currently utilized in the clinic. 
The development of therapeutics to combat CDI represents an urgent and important 
endeavor. With no clear “magic bullet” in-hand, the search for novel targets and 
compounds that act upon these targets will only become more urgent in an increasingly 
dire situation. 
 
1.3 A Case for Targeting Caseinolytic Protease P 
Caseinolytic protease P (ClpP) is a barrel-shaped tetradecameric complex 
composed of two stacked heptameric rings which form a hollow barrel-shaped cylinder.135 
The core is lined with fourteen Serine-Histidine-Aspartic acid catalytic triads, shielded by 
N-terminal loops that cover the axial pore (Figure 1.5A).136 Under normal physiologic 
conditions, ClpP activity is coupled to AAA+ cochaperones (e.g., ClpX and ClpA) that 
selectively bind degron-tagged proteins for degradation.136–138 Degrons are phosphorylated 
arginine residues or ssrA-tags attached to proteins that act as a degradation signal that 
cochaperones recognize as a substrate.138,139 After substrate binding, cochaperones bind to 
ClpP via IGL/F loop motifs that extend from the C-terminal end of each monomer.140,141 
These interact with N-terminal clefts located between monomers.142 The protein is 
translocated in an ATP-dependent process into the proteolytic core of ClpP to be degraded 
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(Figure 1.5B). The ClpP protomer can be divided into three domains: 1) N-terminal head, 
2) C-terminal end, and 3) handle region (Figure 1.5A).143 ClpP adapts two conformations: 
1) the “extended” active form, which interacts with cochaperones and is capable of 
degrading small polypeptides 5-7aa in length, and 2) an autoproteolytically inactive 
compressed form.144,145  
 
Figure 1.5 – Structural overview of ClpP and cochaperone mediated proteolysis.  
A) The extended form of ClpP1 from C. difficile (PDB: 6MX2) is shown at the top, with 
the protomer to the left and the tetradecameric assembly pictured right (side-view = middle, 
top down view = far right). B) ClpP cochaperones, or unfoldases, recognize the degron 
(yellow) and bind with or without the assistance of an adaptor protein. This promotes 
oligomerization of the unfoldase with ClpP via IGL/F motifs located around the axial pore, 
where each monomer makes contact with another. ATP is then consumed to unfold and 
translocate the substrate into the proteolytic chamber of ClpP, where the protein will be 
degraded. Figure 1.5B is reprinted (adapted) with permission from Houry et al.146 
Copyright 2019 American Chemical Society. 
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As a key regulator of virulence and drug resistance in infectious bacteria, 
caseinolytic protease P (ClpP) has emerged as a new target for antibacterial 
development.146 Aberrant ClpP activity (inhibition or activation) induced by small 
molecules is detrimental to microbial fitness, reduces virulent phenotypes, and disrupts 
biofilm formation.147–149 Specifically, activation of ClpP has been validated and proven 
safe in vivo as an antibacterial strategy against systemic lethal infections of Enterococcus 
faecium, E. faecalis (vancomycin-sensitive and -resistant), Staphylococcus aureus 
(methicillin-resistant and -sensitive), and Streptococcus pneumonia. In each case, 
activation of ClpP with a small molecule acyldepsipeptide (ADEP) outperforms clinically 
utilized antibiotics, including linezolid and ampicillin. 
There are several advantages to targeting ClpP: 1) Both inhibition and activation 
are possible, with each tactic affecting different aspects of bacterial pathogenicity.149,150 
This provides an opportunity to determine the therapeutic potential of two orthogonal 
strategies on a single target, a rare phenomenon in antibacterial drug discovery. 2) Due to 
the diverse regulatory roles of ClpP (e.g., growth, motility, virulence, stress response, 
sporulation) disruption of its natural activity would have pleotropic effects that may not be 
easily resolved by compensatory mutations.146 3) ClpP activation itself demonstrates 
efficacy against both actively growing and dormant persister cells,148 a necessity for 
improved antibacterial treatments. 4) In organisms investigated thus far, ClpP is essential 
for pathogenicity, but not survival (with the exception of Mycobacterium tuberculosis).146 
Therefore, inhibiting ClpP may provide a means to negatively affect the virulence of 
pathogens, but preserve the viability of beneficial microbes. 5) Targeting non-essential 
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virulence regulators like ClpP is likely to impair the organism’s infectivity without 
imparting typical selective pressures that drive resistance.  
Despite the advancements in ClpP research, major questions regarding the clinical 
potential of targeting this protease persist. Although the general involvement of ClpP in 
bacterial virulence is well-established, the distinct attributes regulated by ClpP are 
organism dependent. Additionally, while resistance to ADEPs has been generated in 
laboratory settings (Escherichia coli, Bacillus subtilis, E. faecalis, S. pneumoniae, S. 
aureus), all studies have been conducted on single clpP containing organisms. While ClpPs 
from single isoform expressing bacteria have been studied in detail, the function and 
regulation of systems with more than one clpP gene are still poorly understood. 
Interrogating the behavior of ClpP systems in multi-isoform containing organisms is 
expected to reveal additional insight into mechanisms of resistance development that 
should be considered, both during the validation of a target and in its clinical exploitation. 
In these contexts, we are interested in elucidating the behavior, biological relevance, and 
therapeutic potential of the ClpP system in C. difficile. 
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Chapter 2  
Clostridium difficile ClpP Homologs are Capable of Uncoupled Activity 
and Exhibit Different Levels of Susceptibility to Acyldepsipeptide 
Modulation1 
2.1 Abstract 
 Caseinolytic protease P (ClpP) has emerged as a promising new target for 
antibacterial development. While ClpPs from single isoform expressing bacteria have been 
studied in detail, the function and regulation of systems with more than one ClpP homolog 
are still poorly understood. Herein, we present fundamental studies toward understanding 
the ClpP system in C. difficile, an anaerobic spore-forming pathogen that contains two 
chromosomally distant isoforms of ClpP. Examination of proteomic and genomic data 
suggest that ClpP1 is the primary isoform responsible for normal growth and virulence, but 
little is known about the function of ClpP2 or the context required for the formation of 
                                                 
1 Reprinted with permission from: Nathan P. Lavey, Tyler Shadid, Jimmy D. Ballard, and Adam S. Duerfeldt, 
“Clostridium difficile ClpP Homologues are Capable of Uncoupled Activity and Exhibit Different Levels of 
Susceptibility to Acyldepsipeptide Modulation” ACS Infectious Diseases 2019, 5 (1), 79-89 DOI: 
10.1021/acsinfecdis.8b00199. Copyright 2018 American Chemical Society. N.P.L. conducted all 
experiments described herein except for: genomic sequencing performed by OMRF personnel, and qRT-PCR 
experiments conducted by T. Shadid. N.P.L. and A.S.D. designed the research studies, analyzed and 
interpreted the data, wrote, and reviewed the manuscript. J.D.B. provided critical insight, expertise, 
personnel, and facilities and reviewed the manuscript. 
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functional proteases. For the first time in a pathogenic bacterium, we demonstrate that both 
isoforms are capable of forming operative proteases. Interestingly, ClpP1 is the only 
homolog that possesses characteristic response to small molecule acyldepsipeptide 
activation. On the contrary, both ClpP1 and ClpP2 respond to cochaperone activation to 
degrade an ssrA-tagged substrate. These observations indicate that ClpP2 is less 
susceptible to acyldepsipeptide activation but retains the ability to interact with a known 
cochaperone. Homology models reveal no obvious characteristics that would allow one to 
predict less efficient acyldepsipeptide binding. The reported findings establish the 
uniqueness of the ClpP system in C. difficile, open new avenues of inquiry, and highlight 
the importance of more detailed structural, genetic, and biological characterization of the 
ClpP system in C. difficile. 
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2.2 Introduction 
C. difficile infection (CDI) is a leading cause of hospital-acquired illness and 
presents a unique challenge to therapeutic development, as it is both caused by and 
clinically managed with traditional antibiotics that indiscriminately eradicate pathogenic 
and commensal bacteria.1 Importantly, C. difficile is unique from typical beneficial 
microflora, in that it expresses two isoforms of ClpP (ClpP1 and ClpP2).2 To date, our 
understanding of multiple clpP gene expressing organisms is based primarily upon four 
microbes, Synechococcus elongatus,3,4 Listeria monocytogenes,5–9 Pseudomonas 
aeruginosa,10 and M. tuberculosis,11–17 all of which reveal structural disparities and distinct 
regulation profiles of ClpP. 
 
Figure 2.1 Composition and behavior of reported multi-ClpP systems  
“Mixing” denotes that this result was obtained by mixing ClpP1 and ClpP2 
homotetradecamers. 
 
Gene location and expression characteristics of ClpP1 and ClpP2 in C. difficile are 
not only unique from commensal organisms, but also distinct from any pathogenic system 
disclosed to date. Of the two ClpP isoforms contained within the C. difficile genome, clpP1 
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is located in an apparent operon with the cochaperone clpX. Interestingly, clpP2 is 
expressed in a chromosomally distant region of the genome without evidence of proximal 
co-chaperones or adaptors. In previous studies, mass spectrometry-based proteomic 
evaluation and genomic characterization of sporulated and heat-shocked C. difficile 630, 
revealed the presence of ClpP1 and the cochaperones ClpC and ClpX, but no evidence of 
ClpP2.18,19 On the contrary, a microarray analysis completed by Emerson et al. detected 
ClpP1 and ClpP2, with ClpP1 being the only isoform upregulated under pH-induced shock, 
and antibiotic challenge (Amoxicillin, Clindamycin, and Metronidazole).20 clpP2 
transcripts have also been detected in NAP121 and ϕCD38-2 prophage22 containing C. 
difficile variants, suggesting that clpP2 may have involvement in hypervirulent and/or 
resistant phenotypes. Taken together, ClpP1 has been detected in ribotype 630 and 
hypervirulent strains, while the presence of ClpP2 expression or protein has only been 
reported in hypervirulent strains. Nevertheless, these results suggest that contrary to other 
multi-ClpP organisms, which rely on mixtures of ClpP1 and ClpP2 monomers to form the 
functionally relevant protease (Figure 2.1), C. difficile ClpP1 and ClpP2 may operate in 
an uncoupled fashion and exhibit different biological roles. To evaluate the first portion of 
this hypothesis and begin to understand the behavior of the C. difficile ClpP system, we 
overexpressed, purified and reconstituted the homomeric ClpP1 and ClpP2 complexes and 
assessed the activity of these proteases.  
Caseinolytic protease P (ClpP) has emerged as a promising new target for 
antibacterial development. While ClpPs from single isoform expressing bacteria have been 
studied in detail, the function and regulation of systems with more than one ClpP 
homologue are still poorly understood. Herein, we present fundamental studies toward 
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understanding the ClpP system in C. difficile, an anaerobic spore-forming pathogen that 
contains two chromosomally distant isoforms of ClpP. Examination of proteomic and 
genomic data suggest that ClpP1 is the primary isoform responsible for normal growth and 
virulence, but little is known about the function of ClpP2 or the context required for the 
formation of functional proteases. For the first time in a pathogenic bacterium, we 
demonstrate that both isoforms are capable of forming operative proteases. Interestingly, 
ClpP1 is the only homologue that possesses characteristic response to small molecule 
acyldepsipeptide (ADEP) activation. On the contrary, both ClpP1 and ClpP2 respond to 
cochaperone activation to degrade an ssrA-tagged substrate. These observations indicate 
that ClpP2 is less susceptible to ADEP activation but retains the ability to interact with a 
known cochaperone. Homology models reveal no obvious characteristics that would allow 
one to predict less efficient ADEP binding. The reported findings establish the uniqueness 
of the ClpP system in C. difficile, open new avenues of inquiry, and highlight the 
importance of more detailed structural, genetic, and biological characterization of the ClpP 
system in C. difficile. 
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2.3 Results 
2.3.1 Significantly higher transcript levels of clpP1 are observed in exponential and 
stationary growth phases.  
To determine the expression profile of clpP1 and clpP2 during exponential and 
stationary growth phases, we quantified transcript levels utilizing quantitative reverse-
transcriptase polymerase chain reaction (qRT-PCR). Total RNA extracts were isolated 
from C. difficile 630 cells in biological triplicate from both exponential (OD600 = 0.6) and 
stationary (OD600 = 1.2) growth populations in Brain heart infusion-supplemented (BHIS) 
media. As shown in Figure 2.2 (Ct values, Table A.2), clpP1 and clpP2 transcripts were 
detected during both phases of growth, albeit with clpP2 transcripts significantly less 
prevalent than clpP1.  
The observed difference in relative mRNA expression levels, paired with 
previously reported proteomic and transcriptomic data, suggests that clpP1 is the major 
contributor to homeostasis in C. difficile. The detection of clpP2, albeit at a much lower 
transcript level, indicates that clpP2 likely carries some function within the organism, but 
is likely not tied to a large role in general homeostasis. While this speculation is not 
particularly ground-breaking, it does demonstrate that clpP2 is transcribed in both phases, 
a detail that is not obvious from studies described previously. The disparity in transcript 
levels adds confidence to our original hypothesis that unlike other pathogens investigated 
to date, ClpP isoforms in C. difficile are capable of uncoupled activity and are responsible 
for disparate biological roles. The qRT-PCR results compelled us to investigate the 
oligomerization behavior and catalytic profile of reconstituted ClpP1 and ClpP2.  
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Figure 2.2 Relative quantification of clpP1 and clpP2 mRNA expression during 
exponential and stationary growth phases in BHIS broth.  
Transcript levels were normalized to the reference gene rpoB, with clpP2 transcript level 
reported relative to clpP1. The resulting data was analyzed via multiple comparison Two-
way ANOVA and corrected by the Sidak method. ****, P ≤ 0.0001 
 
2.3.2 ClpP1 and ClpP2 share highly conserved sequence homologies and retain key 
structural motifs. 
Within the last 5 years, elegant biophysical studies have revealed ClpP operation to 
be governed by inter- and intramolecular conformational switches that propagate 
regulation signals through the complex.8,23–25 The presence or absence of these hotspots 
may provide an indicator for how uncharacterized ClpP isoforms can be expected to 
function.  Therefore, to determine if critical motifs are conserved, we aligned the primary 
sequences of C. difficile ClpP1 and ClpP2 to B. subtilis ClpP (BsClp; identity: ClpP1-74% 
and ClpP2-63%), an evolutionarily related organism with a well-characterized ClpP 
homolog. As shown in Figure 2.3, the primary sequence alignment reveals that key hotspot 
regions, including the Ser-His-Asp catalytic triad, Tyr63 activation trigger, Asp(Glu)/Arg 
oligomerization sensor domains, and the Gly-rich heptamer dimerization domain, are 
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highly conserved in both C. difficile ClpP isoforms. Although there seems to be significant 
variation in the E-helix domain, a motif involved in heptamer dimerization to form the 
operative tetradecamer, there is no obvious evidence to suggest that either isoform would 
have difficulty oligomerizing or exhibiting stability in the tetradecameric form as a 
homomeric complex. 
 
Figure 2.3 Primary sequence alignment of C. difficile ClpP isoforms (CdClpP1 and 
CdClpP2) and Bacillus subtilis ClpP (BsClpP).  
Alignment and graphic generated with Clustal Omega. Green circles indicate amino acids 
shown to interact with acyldepsipeptides in B. subtilis. 
 
2.3.3 ClpP1 forms a more stable tetradecameric complex. 
Because ClpP1 and ClpP2 share high sequence identity (~72%) and retain key 
structural motifs, we hypothesized that both homologs would form active tetradecameric 
complexes capable of peptide/protein degradation. This however, cannot be assumed, as 
has been demonstrated by the S. elongates, L. monocytogenes, P. aeruginosa, and M. 
tuberculosis studies. To begin the assessment of possible oligomeric configurations of C. 
difficile ClpP1 and ClpP2, we separately expressed and purified each isoform to evaluate 
homogeneous-oligomeric reconstitution. Initially, C. difficile ClpP1 and ClpP2 were 
expressed with C-terminal 6x His-tags in E. coli Rosetta cells, and purified via affinity 
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chromatography before size exclusion chromatography (SEC) was performed to buffer 
exchange and confirm oligomeric status. 
Assessment of purified fractions by SDS-PAGE and SEC suggested pure, 
completely tetradecameric ClpP complexes Identity of ClpP1 and ClpP2 were confirmed 
by high-resolution electrospray mass spectrometry (HR-ESIMS) and peptide digest and 
sequencing experiments. To our surprise, however, E. coli ClpP (EcClpP) was detected in 
~10-30% relative abundance within our purified ClpP1 and ClpP2 preparations. We 
suspect that endogenous EcClpP from the expression cell line co-purified with the C. 
difficile ClpPs and was incorporated into the isolated tetradecameric complex. Given the 
high sequence homology of EcClpP and C. difficile ClpPs, this seems plausible and should 
not be overlooked when reconstituting other complexes prepared from recombinant 
techniques. One might assume that such an impurity would be evident by SDS-PAGE 
analysis, however, no such contamination was evident in our experiments, probably due to 
very similar molecular weights and suboptimal protein loading concentrations and/or gel-
gradients. Unless one is specifically looking for a host-ClpP band and varying experimental 
conditions in attempts to reveal this, it will not likely be evident in typical preparations. As 
such we suggest utilizing a variety of methods to verify a pure and monodisperse 
preparation. To ensure that subsequent biochemical evaluations of these complexes were 
not influenced by contaminating EcClpP, each C. difficile ClpP isoform was overexpressed 
and purified from cells lacking EcClpP (EcClpP, graciously provided by Dr. Robert 
Sauer’s group, MIT).26 Unless otherwise noted, all data presented herein utilizes C. difficile 
ClpP prepared from this ClpP E. coli strain. 
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ClpP1 rapidly tetradecamerizes prior to SEC purification, as indicated by the single 
peak corresponding to the molecular weight of tetradecameric ClpP1. (Figure 2.4A). The 
heptameric ClpP1 oligomer was not observed over the course of multiple purifications. 
ClpP2, however, elutes as a mixture of oligomeric species. If, however, ClpP2 is allowed 
to equilibrate ≥48 h, nearly complete oligomerization to the tetradecameric complex occurs 
(Figure 2.4B). HR-ESIMS confirmed the identity of both isoforms (Appendix A.1) and 
the absence of any contaminating EcClpP. Dynamic light scattering (DLS) experiments 
confirmed tetradecameric assembly for each isoform after purification (Appendix A.2 - 
A.3).  
 
Figure 2.4 Tetradecameric assembly and thermal stability of ClpP1 and ClpP2 
homomeric complexes.  
A) Size exclusion chromatograph of purified recombinant ClpP1 and ClpP2 following Ni-
affinity purification. BsClpP is included for comparison. B) time-dependent 
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oligomerization of ClpP2. An aliquot of ClpP2 was injected onto a S-300 SEC (blue, solid), 
and again 14-days later (blue, dashed). C) and D) SYPRO Orange thermal shift analysis 
(TSA) of tetradecameric ClpP1 (C) and ClpP2 (D) in the presence and absence of varying 
concentrations of an ADEP activator. 
 
To evaluate the relative stability of ClpP1 and ClpP2, both were exposed to thermal 
shift analysis (TSA). As shown in Figure 2.4C, ClpP1 exhibits a Tm=53.2 °C and thus is 
significantly more stable to thermal denaturation than ClpP2 (Tm=46.5 °C). Additionally, 
the presence of a synthetic acyldepsipeptide (100 µM, ADEP, Figure 2.7A) known to 
stabilize other ClpP homologs, results in stabilization of ClpP1 (ΔTm = +11.2 °C, Figure 
2.4C), but an apparent destabilization of ClpP2 (ΔTm = -1.6 °C, Figure 2.4D). ADEP 
destabilization of tetradecameric ClpP complexes has been reported previously,27 and is 
attributed to substoichiometric occupation of ligand binding sites, which leads to disruption 
of the tetradecameric complex. These results hint at a rather drastic difference in ADEP 
interactions between the two isoforms. Nonetheless, both isoforms are capable of forming 
stable homotetradecamers, a feature only observed thus far in M. tuberculosis but has 
recently been disputed.28  
2.3.4 ClpP1 exhibits prototypical peptidolysis.  
When in an extended conformation, the catalytic triad of ClpP is aligned and 
capable of degrading small peptides (<5–6 amino acids) without the requirement of a 
cochaperone or ATP.29 As exemplified by studies on M. tuberculosis ClpP isoforms, 
formation of a stable tetradecamer does not signify catalytic competency. To determine 
whether or not the assembled homo-oligomeric ClpP1 and ClpP2 complexes exist in the 
extended confirmation and have active (i.e., aligned) catalytic triads, we evaluated the 
capability of each ClpP tetradecamer to degrade two fluorescently labeled peptides, Suc-
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Leu-Tyr-aminomethylcoumarin (dipeptide, SLY-AMC)29 and Z-Gly-Gly-Leu-AMC 
(tripeptide, Z-GGL-AMC).11 The small peptides freely diffuse into the proteolytic chamber 
of ClpP, where, in the presence of an active catalytic Ser-His-Asp triad, the peptides are 
hydrolyzed, releasing quantifiable fluorescence. As shown in Figure 2.5A, ClpP1 degrades 
SLY-AMC in a time dependent manner and exhibits Michaelis-Menten kinetics (Figure 
2.5B), while ClpP2 fails to induce appreciable degradation. In fact, neither increased time 
(<24 h) nor alterations in substrate concentration produced measurable ClpP2 mediated 
degradation of this substrate (data not shown). Both ClpP1 and ClpP2 are, however, able 
to hydrolyze Z-GGL-AMC, although ClpP2 is not nearly as efficient as ClpP1 and requires 
extended co-incubation periods (>30 h) with this substrate to see appreciable hydrolysis 
(Figures 2.5C and 2.5D). Mixing equal concentrations of homomeric ClpP1 and ClpP2 
resulted in less peptidolysis for both SLY-AMC and Z-GGL-AMC (Appendix A.6) than 
ClpP1 alone. Native gel assessment of the mixture revealed no evidence of a new 
heteromeric species (Appendix A.7) While this experiment is a rather crude assessment, it 
provides evidence that disassembly of homomeric complexes and reassembly into more 
active heteromeric complexes is not thermodynamically favored and does not occur in 
vitro. 
The Z-GGL-AMC results suggest, however, that the catalytic triad for ClpP2 is 
aligned to some extent under the evaluated conditions, but that experimental (e.g. buffer 
composition) and/or structural nuances dictating substrate specificity may exist for each 
ClpP isoform. Further evidence supporting that both complexes exhibit an aligned catalytic 
triad, arises upon incubation of each with ActivX TAMRA-FP, a fluorescent probe that 
selectively tags active serine hydrolases.30 As shown in Figure 2.5E, TAMRA-FP labels 
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ClpP1 efficiently, while reacting to a lower extent with ClpP2. It is worth noting that in all 
three of these experiments C. difficile ClpP samples prepared from Rosetta DE3 cells 
(contaminated with EcClpP) were assessed in parallel with samples prepared from the 
ΔEcClpP strain and no significant differences in behavior were observed. Likewise, we 
failed to notice any difference in thermal stability of ClpP complexes prepared from either 
strain. So, while EcClpP contamination exists in the Rosetta DE3 preparations, its presence 
does not seem to affect the activity of either complex. We imagine this may not be the case 
for other ClpP homologs, especially those that exhibit lower homology, and caution others 
utilizing endogenous ClpP expressing cell lines for the characterization of recombinant 
ClpP complexes. 
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Figure 2.5 Peptidolytic activity of ClpP1 and ClpP2 
A) time-dependent degradation of SLY-AMC by ClpP1 expressed from EcClpP cells 
(black, solid, solid triangle), ClpP1 from Rosetta DE3 (black, dashed, hollow triangle), 
ClpP2 from EcClpP (blue, solid, solid square), ClpP2 from Rosetta DE3 (blue, dashed, 
hollow square). Experiments conducted with 1 µM ClpP tetradecamer and 0.5 mM SLY-
AMC. B) Michaelis-Menten analysis of ClpP1 and ClpP2 degradation of SLY-AMC. 
ClpP1 (DE3) Vmax = 1213 ± 38.0; ClpP1 (EcClpP) Vmax = 1357 ± 39.9. ClpP2 Vmax values 
were not determined due to relatively negligible cleavage of the substrate. C) time-
dependent (0-30 min) degradation of Z-GGL-AMC by ClpP isoforms. Experiments 
conducted with 1 µM ClpP tetradecamer and 0.1 mM Z-GGL-AMC. D) degradation of Z-
GGL-AMC by ClpP isoforms after extended periods (30 h and 46 h) of incubation. Means 
of each dataset were compared to the control (Z-GGL-AMC alone) at each time point, for 
statistical significance within a 95% confidence interval by two-way ANOVA analysis, 
with Dunnett’s multiple comparison test. (**, P < 0.05). E) serine-protease active site 
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labeling with ActivX TAMRA-FP visualized in an SDS-PAGE gel with Chymotrypsin 
(CHY) as a positive control.  
 
While investigating potential reasons for the lack of ClpP2 proteolytic activity, we 
determined through HR-ESIMS that ClpP2 was capable of forming disulfide bonds 
(reversible with dithiothreitol (DTT) addition) that may affect enzymatic efficiency. 
DiANNA, a web server developed by Boston College to define cysteine oxidation states 
and predict disulfide bond partners, identified two potential disulfide bonds (i.e., Cys86-
Cys92, and Cys92-Cys113, Appendix A.4) for ClpP2. The algorithm reveals disulfide 
bond formation to be unique to ClpP2, as ClpP1 contains only a single cysteine. Since the 
two predicted disulfide bonds in ClpP2 are located in proximity to the catalytic triad, we 
could not discount that disulfide bond formation may dictate proteolytic activity or 
cleavage specificity by misshaping the topology around serine catalytic site, or locking 
ClpP2 in an inactive conformation. Therefore, we also evaluated the activity of ClpP2 in 
the presence of varying concentrations of DTT, but found that this failed to stimulate 
proteolytic activity, even at incubation times exceeding 48 h (Appendix A.5). It is also 
worth noting that reduced conditions (expected for an anaerobic environment) had no 
significant effect on the thermal stability of ClpP1 or ClpP2. 
2.3.5 ClpP1 and ClpP2 respond to ClpX activation. 
As mentioned previously, ClpP proteolysis of targeted substrates is tightly 
regulated via coordination between ATP-dependent cochaperones (e.g., ClpX, ClpA, 
ClpC). These cochaperones recognize degron sequences (e.g., ssrA) that tag proteins for 
degradation by ClpP.11 Because clpP1 and clpX are situated in an apparent operon in C. 
difficile, we anticipated that ClpP1 and ClpX would readily combine to form an operative 
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heteroprotein complex capable of degrading ssrA-tagged substrates. We however, did not 
know what to expect with ClpP2, as the lack of proteolytic activity in the SLY-AMC assay 
is not necessarily indicative of the capability to function with natural co-chaperones.  To 
determine the ability of each C. difficile ClpP homolog to form the ClpP:ClpX proteolytic 
machinery and degrade protein substrates we expressed and purified C. difficile ClpX and 
ssrA-tagged green-fluorescent protein (ssrA-GFP) to allow for reconstitution of the 
“natural” proteolytic machinery. 
ClpX and ssrA-GFP were incubated with each ClpP isoform in order to determine 
if ssrA-GFP degradation could be mediated by ClpX. We observed reductions in GFP gel-
band intensity for both ClpP isoforms with ClpX and ATP present (Figure 2.6A), with 
ClpP1 once again outperforming ClpP2. Incubation of ssrA-GFP with each ClpP isoform 
in the absence of ATP revealed no degradation of the substrate, indicating that the observed 
degradation is induced by ClpX (Figure 2.6B). It is well-known that ClpX ATP hydrolysis 
is repressed upon engagement with ClpP.31,32 As such, we determined ATP hydrolysis rates 
for ClpX in the presence of either ClpP1 or ClpP2. As seen in Figure 2.6C, ClpX ATPase 
hydrolysis decreases when incubated with either ClpP1 (~18% rate reduction) or ClpP2 
(~7% rate reduction). 
 
Figure 2.6 ClpXP mediated degradation of ssrA-GFP and ClpP induced reduction in 
ATP hydrolysis.  
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A) ClpXP1 and ClpXP2 mediated degradation of ssrA-GFP. Experiment was performed in 
triplicate and SDS-PAGE results were quantified with ImageJ results (graph). B) Fraction 
of ssrA-GFP remaining when incubated with ClpP variants in the absence of ClpX. C) the 
rate of C. difficile ClpX ATP hydrolysis in the presence or absence of C. difficile ClpP1 or 
ClpP2. C. difficile ClpX hydrolyzed ATP at a rate of 149.2  6.0 min-1•ClpX6-1. In the 
presence of ClpP1 ClpX hydrolyzed ATP at a rate of 122.5  0.3 min-1•ClpX6-1. In the 
presence of ClpP2 ClpX hydrolyzed ATP at a rate of 138.7  0.4 min-1•ClpX6-1. Km values 
for ClpX, ClpP1, and ClpP2 are 375.2 µM, 318.9 µM, and 402.9 µM, respectively. 
 
In an attempt to elicit ClpP2 peptidolytic activity, we added SLY-AMC to an 
aliquot of the ClpX:ClpP2 reaction. The rationale was that perhaps the ClpX interaction 
may trigger an autocatalytic-processing, or other maturation event, giving rise to 
peptidolytic activity. However, no degradation of SLY-AMC was observed. 
2.3.6 ClpP1 and ClpP2 exhibit significant differences in susceptibility to chemo-activation.  
ADEPs (Figure 2.7A) bind and activate bacterial ClpP in a cochaperone and ATP-
independent manner, resulting in unselective proteolysis and bacterial cell death.33 Similar 
to the natural cochaperones, ADEP binding results in a large conformational shift and a 
subsequent widening of the proteolytic chamber.14 In the case of chemo-activation, 
however, the proteolysis is uncontrolled and unregulated, and thus detrimental to bacterial 
survival.34 Analysis of co-crystal structures reveals that the ADEPs mimic the natural 
isoleucine/leucine-glycine-phenylalanine (I/LGF) loop utilized by AAA+ cochaperones 
for ClpP binding and thus bind competitively to the same pocket.34,35 As such, activators 
of ClpP operate via two mechanisms of action: 1) activating the ClpP protease and inducing 
unselective degradation; and 2) inhibiting the interaction of AAA+ cochaperones with 
ClpP, thus disrupting the ability of cochaperones to deliver natural substrates for 
degradation. Therefore, bacterial cells treated with ClpP activators suffer from 
simultaneous self-digestion and a build-up of toxic substrates, resulting in a dual attack on 
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microbes. Recent interest in pursuing ADEPs for CDI treatment has appeared in literature, 
but no experimental assessment has followed.36 
 
Figure 2.7 Susceptibility of ClpP1 and ClpP2 to ADEP activation.  
A) Synthetic ADEP utilized in these experiments. B) dose-dependent ADEP-induced 
degradation of the decapeptide Abz-DFAPKMALVPYNO2. C) Time-dependent ADEP 
(100 µM) induced degradation of FITC β-casein; ClpP1 (black, triangles) and ClpP2 (blue, 
squares). 
 
To determine the susceptibility of homomeric ClpP1 and ClpP2 to ADEP 
activation, we incubated both isoforms with serially-diluted concentrations of a synthetic 
ADEP (Figure 2.7A) in the presence of a self-quenching decapeptide (Abz-
DFAPKMALVPYNO2) or FITC-β-casein. Upon ADEP mediated activation, ClpP will 
degrade the self-quenching substrate and release quantifiable fluorescence. As shown in 
Figure 2.7, ClpP1 displays a prototypical response to ADEP activation, and efficiently 
degrades both the decapeptide (Figure 2.7B) and protein (Figure 2.7C) substrates. ClpP2 
on the other hand, demonstrates a much lower susceptibility to ADEP activation and fails 
to produce significant levels of peptidolysis or proteolysis, even at ADEP concentrations 
as high as 1 mM. 
2.3.7 Homology Models Reveal No Obvious Preclusions in ClpP2 Activating Pocket 
Intrigued by the response of ClpP2 to co-chaperone activation while exhibiting 
significantly less susceptibility to ADEP activation, we generated homology models to aid 
in visualization of the ADEP binding pocket and elucidate any amino acid substitutions 
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that may preclude ADEP binding. ClpP from Bacillus subtilis exhibits 74% and 63% 
sequence identity to C. difficile ClpP1 and ClpP2, respectively and was thus utilized to 
generate the models (SWISS-MODEL). Assessment of the primary sequences (Figure 2.3) 
and models (Figure 2.8), however, failed to reveal any obvious amino acid substitutions 
that would allow one to predict less efficient ADEP binding. This leaves us to speculate 
that alterations in the primary sequence outside of the cochaperone/ADEP binding pocket 
may lead to subtle perturbations of higher order ClpP structures that result in ADEP 
insensitivity while maintaining natural function. Adding intrigue to this speculation is an 
observation that in hypervirulent strains of C. difficile, the primary sequence of ClpP1 and 
ClpP2 retain complete sequence identity to C. difficile 630, but include three FT amino 
acid insertions. Studies are ongoing to determine the effect of those insertions on ClpP1 
and ClpP2 functionality. Systematic insertions of this type in other ClpP isoforms has not 
been previously reported, nor do they occur in characteristic structural motifs relevant to 
ADEP activation.  
 
Figure 2.8 Depiction of the A) ClpP1 and B) ClpP2 ADEP binding pockets based on 
homology modeling with Bacillus subtilis ClpP.  
Prime numbers indicate one ClpP subunit and non-prime numbers another. Gray indicates 
the culled surface of ClpP with a solvent radius set to 2.0 Å. 
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2.3 Conclusion 
Reported mechanisms of evolved resistance to ADEP activation include efflux 
pump upregulation and point mutations close to the active site (e.g., T182A), resulting in 
impaired proteolytic activity. Both of these observations were obtained from E. coli. 
Unspecified point mutations that eliminate proteolytic activity have also been generated in 
a laboratory setting at a frequency range of 106 in E. faecalis and S. pneumoniae. All of 
these studies have been conducted in single ClpP gene containing organisms. We believe 
that more complex resistance or redundancy mechanisms may exist in multi-ClpP 
organisms and that studying these systems will reveal new insights into ClpP modulation 
as a therapeutic strategy and possible resistance evolution. Analysis of previous C. difficile 
genomic and proteomic studies indicated that the ClpP system in this organism may exhibit 
a behavior distinct from other multi-ClpP organisms interrogated to date and thus inspired 
us to begin studying this system in C. difficile. 
The data demonstrate that the proteolytic activity and susceptibility to chemo-
activation differ between C. difficile ClpP1 and ClpP2 and that these two isoforms are 
capable of functioning in an uncoupled fashion. This has yet to be observed in other multi-
clpP organisms (e.g., M. tuberculosis, L. monocytogenes, S. elongatus), which require both 
ClpP1 and ClpP2 to form functionally relevant heterotetradecameric proteolytic 
complexes. Recently, it was reported that ClpP1 and ClpP2 of P. aeruginosa exhibit 
different expression profiles and disparate biological roles, but reconstitution of an active 
or fully assembled ClpP2 homomeric complex could not be obtained in vitro. Thus, to the 
best of our knowledge, for the first time in a multi-clpP organism, we demonstrate that 
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both isoforms are capable of forming operative proteases. These results clearly differentiate 
the ClpP system of C. difficile and highlight the possibilities of 1) uncoupled function of 
ClpP isoforms in pathogenic bacteria and 2) selective or specific modulation of one isoform 
over another. 
The studies presented herein lay a foundation for more detailed characterization of 
the structure, function, and behavior of the ClpP system in C. difficile, as many questions 
remain to be answered. For example, is it possible for ClpP1 and ClpP2 to form operable 
heterogenous tetradecamers like those exhibited by S. elongates, M. tuberculosis, and L. 
monocytogenes? If so, how does the activity and susceptibility to chemo-modulation 
compare to the homogenous complexes? This question is not one that can be answered 
merely by mixing the two isoforms together. Rather, extensive protein science and 
analytical work are necessary to assess heteromeric formation and to determine the 
stoichomeric ratio of each isoform. What are the structural nuances that differentiate 
operative ClpP complexes and their responses to ADEP activation? This question is 
particularly interesting because no obvious characteristics emerge during the analysis of 
the primary sequences. Answering this question will likely require structural 
characterization of these complexes. While continued biochemical and biophysical 
evaluation of reconstituted C. difficile ClpP complexes will undoubtedly lead to new 
insights about enzyme kinetics and structure, genetic manipulation of the ClpP system in 
C. difficile is essential to understanding the biological significance and therapeutic 
potential. These studies are ongoing, and results will be presented in due course.  
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2.4 Materials and Methods 
Unless otherwise noted, all ClpP concentrations are expressed as the 
tetradecameric (ClpP14) protease.  
2.4.1 Expression and Purification of ClpP1 and ClpP2.  
clpP1 (YP_001089821.1) and clpP2 (YP_001089868.1) were synthesized with a 
Poly-His(6x) C-terminal tag, codon optimized, and cloned into pET28a by Genscript USA 
(Piscataway, NJ). clpX (YP_001089820.1) with a TEV-cleavable Poly-His(6x) N-terminal 
tag was also synthesized by Genscript USA, codon optimized, and cloned into pET21a. All 
plasmids were transformed into Rosetta (DE3) and EcClpP (DE3) cells (a gracious gift 
from Dr. Robert Sauer’s laboratory) for expression, through standard techniques. M4100 
(DE3) cells (EcClpX) possessing ssrA-tagged (LAA)-GFP with a Poly-His(6x) N-
terminal tag was provided as a gracious gift from Dr. Tania A. Baker’s laboratory, and was 
expressed and purified as previously described.17 All purified proteins were flash frozen in 
liquid N2 and stored at -80 °C until needed.  
To express ClpP1, ClpP2, and ClpX, a 4L culture was inoculated with an overnight 
stock (1:100) and grown to an OD600 of 0.5 – 0.7, shaking at 250rpm at 37 °C. Prior to 
induction with 1 mM IPTG, the temperature was decreased to 18 °C and shaking was 
reduced to 180 rpm. Overexpression was carried out over 16-18 h at 18 °C, shaking at 180 
rpm. The bacteria were pelleted via centrifugation (5000 g, 4 °C, 15 min). The pellet was 
washed with ice-cold lysis buffer, and stored at -80 °C until lysis. For isolation and 
purification of ClpP1 and ClpP2, the pellet was resuspended in ice-cold lysis buffer (50 
mM Tris pH 8.0, 200 mM NaCl, 10% glycerol), before being loaded into an Emulsiflex 
cell-disruption system, for four-rounds of lysis at ~15000 psi while being cooled on ice. 
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The lysate was clarified via centrifugation (28500 g, 4 °C, 45 min) and loaded onto a 5 mL 
HF His-Trap column (GE Healthcare) via an NGC Explorer FPLC (Bio-Rad) at 4 °C. The 
column was washed with 5% His-elution buffer (Tris pH 8.0, 200 mM NaCl, 10% glycerol, 
500 mM imidazole) for 20 column volumes (CV). His-tagged protein was eluted with a 
step-wise increase of Elution Buffer (10/15/30/70/100%), in reverse-flow. Highly pure 
fractions were collected in 5 mL intervals and concentrated to ~5 mL before injection onto 
a HiPrep 16/60 Sephacryl S-300 HR Size Exclusion Column (GE Life Sciences). ClpP was 
exchanged into activity buffer (25 mM HEPES, 100 mM KCl, 5 mM MgCl2, 1 mM DTT, 
10% glycerol) with an NGC Explorer FPLC at 4 °C. ClpP was concentrated with a 50 kDa 
MW-cutoff concentrator, and flash frozen until needed. All proteins expressed in the 
ΔEcClpP cell line were purified identically, except for induction of expression was 
accomplished with 0.5 mM IPTG. 
Both isoforms express well in EcClpP cells, and are stable at 4 °C for >1-month. 
Typical ClpP1 and ClpP2 protein expression yields range from 15-25 mg/mL and 7.5-12.5 
mg/mL, respectively. ClpP1 can be concentrated to ~60 mg/mL without any sign of 
precipitation, while ClpP2 exhibits less stability at concentrations exceeding 12.5 mg/mL. 
Samples were flash frozen in activity buffer (25 mM HEPES, 100 mM KCl, 5 mM MgCl2, 
1 mM DTT, 10% glycerol) and stored at -80 ˚C until further use. 
For isolation and purification of ClpX, the pellet was resuspended in ice-cold ClpX 
lysis buffer (50 mM Tris-Cl pH 8.8, 200 mM NaCl, 100 mM KCl, 20 mM imidazole, 10% 
glycerol). Cells were lysed, and the lysate was clarified in an identical manner to ClpP1 
and ClpP2. The clarified lysate was then loaded onto a 5 mL HF His-Trap column, and 
washed/eluted similar to ClpP1 and ClpP2, except the concentration of imidazole in the 
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His-elution buffer was decreased 300 mM. Fractions were pooled and concentrated to ~5 
mL, and buffer exchanged via SEC into ClpX activity buffer (50 mM HEPES pH 7.6, 200 
mM KCl, 100mM NaCl, 20 mM MgCl2, 1 mM DTT, 10% glycerol). ClpX fractions were 
concentrated with a 10 kDa MW-cutoff Amicon Ultra concentrator. All assay protein 
concentrations were obtained via A280 nm readings and are reported as tetradecameric 
concentrations unless otherwise stated. 
2.4.2 RNA extraction, cDNA preparation, Quantitative Reverse-Transcriptase PCR, and 
Genomic DNA isolation.  
Freezer stocks of C. difficile 630 were struck onto BHIS agar plates and grown at 
37 °C in a Coy vinyl anaerobic chamber (85% N2, 5% H2, and 10% CO2). In biological 
triplicate, single colonies were picked and used to inoculate ~5 mL of BHIS media. When 
the absorbance reached OD600 of ~0.6 (exponential phase) and ~1.2 (stationary phase) the 
cultures were harvested. Samples were added directly to 2x volume of RNAprotect 
Bacteria Reagent (Qiagen) centrifuged at 5,000 x G, 25 °C for 10 minutes, decanted then 
stored at -20°C until further use. RNeasy Mini kit (Qiagen) was used to isolate the total 
RNA as described by the manufacturer. Contaminating genomic DNA was removed from 
the total RNA samples by two rounds of treatment using TURBO DNA-free kit 
(Invitrogen). cDNA was generated with the SuperScript IV VILO cDNA synthesis kit 
(Thermo) from 1 μg of total RNA, in 20 μL reactions. Appropriate no RT and no template 
control samples were performed alongside each biological replicate. 1 μL of the cDNA 
reaction mixture was added to 12.5 μL 2X qPCR iTaq Universal SYBR Green Supermix 
(Bio-Rad), 10 nM of the forward and reverse primers, and DNAse/RNase free water was 
added to bring the total PCR reaction volume to 25 μL. A 7500 Fast Real-Time PCR 
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System (Applied Biosystems) was used to perform qPCR (See Table A.1 for primers) for 
40 cycles of amplification at 51.5 °C. qRT-PCR primers were designed utilizing the 
PrimerQuest tool by Integrated DNA Technologies. Each primer was then put into the 
NCBI BLAST program to confirm no off-target hits. Primer efficiencies were calculated 
for each set of primers and are as follows rpoB = 99.1%, clpP1 = 97.1%, and clpP2 = 
97.8%. Expression of clpP1 and clpP2 was normalized to the reference gene rpoB, with 
the results calculated via the comparative cycle threshold method.18 
As previously stated, freezer stocks of C. difficile 630 were struck onto BHIS agar 
plates and grown at 37°C in anaerobic chamber. Then a single colony was picked and used 
to inoculate ~5 mL of BHIS media. Genomic DNA was isolated using GenElute Bacterial 
Genomic DNA kit and purified using Zymo Genomic DNA Clean and Concentrator kit, 
following manufacturer’s protocols. 
2.4.3 FITC-β-Casein Proteolysis Assay.  
260 nM ClpP in activity buffer was incubated with ADEP (serially diluted from 
500 µM) at 37 °C for 15 min in flat bottom, nonbinding, nonsterile, white polystyrene 96-
well plates (Corning 3990). After the preincubation period 1 μL 100X FITC-β-casein stock 
was added to each well to give a final concentration of 4.5 μM FITC-β-casein and final 
well volume of 100 μL. Assay plates were then incubated at 37 °C, and hydrolysis of the 
fluorogenic substrate was monitored via an i-TECAN Infinite M200 plate reader 
(excitation: 485 nm; emission: 538 nm). Readings were taken every 30 min for 6 h.  
2.4.4 SLY-AMC & Z-GGL-AMC Peptidolysis Assays.  
All reactions were performed in activity buffer. Reactions contained 1 uM ClpP 
and were performed at 30 °C unless otherwise specified. SLY-AMC was dissolved in 
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DMSO at a stock concentration of 5 mM that was aliquoted into a 2x SLY-AMC master 
mix containing nanopure water and 10% DMSO. 200 μL reactions were assembled in 2x 
concentrations, and three 50 μL 2x reactions were dispensed into black 96-well plates. 
Reactions were started by adding 50 μL of 2x SLY-AMC, and a 0 hr reading was taken 
(excitation: 380nm / emission: 440nm) before incubation at 30 °C. Hydrolysis of the 
fluorogenic substrate was monitored via an i-TECAN Infinite M200 plate reader and 
readings were taken at the time points indicated in the reported data. 
2.4.5 Decapeptide Degradation Assay.  
Assays were performed with 25 nM ClpP in activity buffer supplemented with 5% 
DMSO. ADEP was serially diluted and pipetted into the plate at 10X concentration, before 
a ClpP master mix was added, and both were incubated at 30 °C for 15 min in flat bottom, 
nonbinding, nonsterile, black polystyrene 96-well plates (Grenier). After the preincubation 
period 1 μL of 1.5 mM Abz-DFAPKMALVPY-NO2 (Biomatik) solution was added to each 
assay well to give a final assay concentration of 15 μM fluorogenic decapeptide and final 
assay volume of 100 μL. Assay plates were incubated at 30 °C, and hydrolysis of the 
fluorogenic peptide was monitored via an i-TECAN Infinite M200 plate reader (excitation: 
320 nm; emission: 420 nm). Readings were taken at the time points indicated in the 
reported data. The data was normalized to a 5% DMSO + peptide negative control. 
2.4.6 ssrA-GFP Degradation Assay.  
ClpP1 and ClpP2 were separately co-incubated with ClpX at 25 °C in ATPase 
buffer for 1 h prior to the start of the assay. An ATP-regeneration system containing 75 
μg/mL creatine kinase and 5 mM creatine phosphate was used. All components were 
freshly prepared prior to addition to the reaction. The final concentration of ClpP and ClpX 
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were 400 nM, and 100 nM respectively. 2 μM of ssrA-GFP was added prior to the addition 
of ATP. All controls were incubated for 6 h at 30 °C. The reactions were initiated by 
addition of ATP in ATPase buffer to a final concentration of 4 mM, into a master reaction 
mixture which were distributed into 50 uL aliquots, placed onto a 30 °C heat block, and 
covered in foil. Reactions were then quenched each hour with 95 °C Laemmli buffer. 10 
μL of each reaction was loaded into individual wells of a 4-20% SDS-PAGE gel. 
Experiments were performed in triplicate and intensities were analyzed with ImageJ. The 
fraction of ssrA-GFP remaining was calculated at each time point by dividing the intensity 
ssrA-GFP band by the intensity of the ssrA-GFP + ClpP control. 
2.4.7 ssrA-GFP ATPase Hydrolysis Assay.  
ClpP1 and ClpP2 were separately co-incubated with ClpX at 25 °C in ATPase 
buffer (50 mM HEPES pH 7.6, 10 mM Tris pH 7.6, 100 mM KCl, 20 mM MgCl2, 1mM 
DTT, 10% glycerol, 0.032 NP-40, 0.01% Triton X-100) for 1 h prior to the start of the 
assay. An ATP-regeneration system19 was utilized to monitor ATP-hydrolysis by ClpX via 
absorbance measurements taken at 340 nm in clear 96-well plates. Final concentrations of 
the ATP-regeneration assay were: 1 mM NADH, 20U Lactate dehydrogenase/Pyruvate 
kinase, 7.5 mM phosphoenolpyruvate. All components were freshly prepared prior to 
addition to the reaction. The final concentration of ClpP and ClpX were 200 nM, and 50 
nM, respectively. The reaction was initiated by addition of ATP in ATPase buffer, and 
measurements were taken every 2 min over the course of 4 h to ensure assay completion. 
Initial rates were processed in Microsoft Excel, and transferred to GraphPad Prism for 
Michaelis-Menten and statistical analysis. 
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2.4.8 Thermal Shift Assay.  
The procedure was performed as previously described7 with slight modifications. 1 
μM of ClpP1 in activity buffer was incubated in the presence or absence of ADEP for 15 
min at 37 °C prior to addition of SYPRO Orange (2x final concentration), final reaction 
volume 200 μL. The reaction was then allowed to equilibrate at room temperature in the 
dark for 15 min before dispensing 50 μL aliquots into 96-well plates in triplicate, sealed 
with optically clear microplate tape, and centrifuged briefly to remove bubbles. Thermal 
shift analysis was carried out on a CFX96 Real-Time System (Bio-Rad), heating from 25 
°C to 85 °C in 0.3 °C increments, measuring fluorescence every 1-minute in FRET mode. 
The data was then processed in GraphPad Prism and fit to a Boltzmann distribution curve 
after normalization. 
2.4.9 Mass Spectrometry Analysis of Oligomeric Species.  
ClpP proteins in solution were reduced with DTT, alkylated with iodoacetamide 
and digested with trypsin according to standard protocols. Liquid chromatography tandem 
mass spectrometry was performed by coupling a nanoAcquity UPLC (Waters Corp., 
Manchester, UK) to a Q-TOF SYNAPT G2S instrument (Waters Corp., Manchester, UK). 
Each protein digest (about 100 ng of peptide) was delivered to a trap column (300 μm × 50 
mm nanoAcquity UPLC NanoEase Column 5 μm BEH C18, Waters Corp, Manchester, 
UK) at a flow rate of 2 μL/min in 99.9% solvent A (10 mM ammonium formate, pH 10, in 
HPLC grade water). After 3 min of loading and washing, peptides were transferred to 
another trap column (180 μm × 20 nanoAcquity UPLC 2G-V/MTrap 5 μm Symmetry C18, 
Waters Corp., Manchester, UK) using a gradient from 1% to 60% solvent B (100% 
acetonitrile). The peptides were then eluted and separated at a flow rate of 200 nL/min 
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using a gradient from 1% to 40% solvent B (0.1% formic acid in acetonitrile) for 60 min 
on an analytical column (7.5 μm × 150 mm nanoAcquity UPLC 1.8 μm HSST3, Waters 
Corp, Manchester, UK). The eluent was sprayed via PicoTip Emitters (Waters Corp., 
Manchester, UK) at a spray voltage of 3.0 kV and a sampling cone voltage of 30 V and a 
source offset of 60 V. The source temperature was set to 70 °C. The cone gas flow was 
turned off, the nano flow gas pressure was set at 0.3 bar, and the purge gas flow was set at 
750 mL/h. The SYNAPT G2S instrument was operated in data-independent mode with ion 
mobility (HDMSe). Full scan MS and MS2 spectra (m/z 50–2000) were acquired in 
resolution mode (20 000 resolution fwhm at m/z 400). Tandem mass spectra were generated 
in the trapping region of the ion mobility cell by using a collisional energy ramp from 20 
V (low mass, start/end) to 35 V (high mass, start/end). A variable IMS wave velocity was 
used. Wave velocity was ramped from 300 to 600 m/s (start to end), and the ramp was 
applied over the full IMS cycle. A manual release time of 500 μs was set for the mobility 
trapping and a trap height of 15 V with an extract height of 0 V. The pusher/ion mobility 
synchronization for the HDMSe method was performed using MassLynx V4.1 and 
DriftScope v2.4. LockSpray of glufibrinopeptide-B (m/z 785.8427) was acquired every 60 
s and lock mass correction was applied post acquisition. 
Raw MS data were processed by PLGS (ProteinLynx Global Server, Waters Corp., 
Manchester, UK) for peptide and protein identification. MS/MS spectra were searched 
against the Uniprot E.Coli database and the C. difficile database (4,322 reviewed proteins 
and 7,753 unreviewed proteins respectively) and with the following search parameters: full 
tryptic specificity up to two missed cleavage sites, carbamidomethylation of cysteine 
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residues set as a fixed modification, and N-terminal protein acetylation and methionine 
oxidation. 
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Chapter 3  
Phenotypic Response from the  
Loss of ClpP Function in Clostridium difficile2 
3.1 Abstract 
 Multiple antibiotic resistant Clostridium difficile has continued to plague hospitals 
and long-term care facilities for the last few decades, and represents a massive burden to 
the global healthcare community. C. difficile is an anaerobic pathogen that produces 
aerotolerant spores, which enables transmission to other hosts. Despite this, the process of 
sporulation is not well understood in C. difficile. However, sporulation has been researched 
extensively in a similar Gram-positive organism, Bacillus subtilis, where it was shown that 
loss of caseinolytic protease P (ClpP) function resulted in an asporogenic phenotype. 
Herein we demonstrate that each ClpP homolog maintains both distinct and shared roles in 
regulating sporulation in C. difficile. The loss of ClpP1 function appears to lead to stalled 
engulfment while loss of ClpP2 function may accelerate the production of small 
compartments. The total loss of ClpP function abolishes engulfment which precludes 
                                                 
2 This chapter is adapted from a manuscript currently under preparation. The authors are: Nathan P. 
Lavey, Tyler Shadid, Jimmy D. Ballard, and Adam S. Duerfeldt. N.P.L. conducted all experiments described 
herein except CRISPR/Cas9 mutagenesis experiments conducted solely by T.S. which produced the ClpP 
mutants, and where specifically mentioned. N.P.L. and A.S.D. designed the research studies, analyzed and 
interpreted the data, and wrote and reviewed the manuscript. J.D.B. provided critical insight, expertise, 
personnel, and facilities and reviewed the manuscript. 
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sporulation, demonstrating the therapeutic potential for disrupting the ClpP system in C. 
difficile.   
3.2 Introduction  
C. difficile transmission hinges upon the production of aerotolerant spores, which 
spread via the fecal-oral route and propagate infection.1–4 Despite this knowledge, strategic 
targeting and inhibition of sporulation to obviate the transmission cycle remains 
underexplored.5–7 Major reasons for the lack of anti-sporulating approaches are that the 
regulatory machinery surrounding sporulation in C. difficile remains poorly understood and 
tractable targets affecting this process are limited.8 Recently, several drugs have entered 
clinical trials aiming to reduce transmission through the disruption of sporulation or 
germination; however, none of these leads demonstrate a unique mode of action, or directly 
interfere with known sporulation mechanisms.8 Vancomycin, metronidazole, and 
fidaxomicin are the most commonly prescribed drugs for CDI, however, their use promotes 
microfloral imbalance and predisposes patients to infection and/or recurrence.7,9 
Identifying new drug targets involved with sporulation is important and successful 
drugging of these targets would be transformative to CDI treatment, as halting sporulation 
would break the transmission cycle and thus simultaneously address the pathological and 
transmissive features of CDI. 
Caseinolytic protease P (ClpP) has emerged as an attractive antibacterial target due 
to its global regulatory roles in cell developmental and stress response.10,11 Although the 
general roles of ClpP in bacterial virulence are evolutionarily conserved, the distinct 
attributes regulated by ClpP are organism dependent and have not been defined in C 
difficile. In the closely related Gram-positive organism Bacillus subtilis, ClpP and its 
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cognate chaperones (e.g., ClpX and ClpC) regulate key pathways that influence sporulation 
and virulence. For example, ClpXP regulates early-stage sporulation by degrading the 
checkpoint polypeptide Sda, which inhibits sporulation in response to DNA damage.12,13 
On the other hand, ClpCP initiates early forespore maturation by indirectly activating F 
through the degradation of SpoIIAB.14,15 No ortholog of Sda is present in C. difficile but 
the RNA polymerase sigma factors (σ) and sporulation regulatory proteins (Spo-) are 
highly conserved.16 
The ClpP system in C. difficile expresses two ClpP isoforms, ClpP1 and ClpP2, 
while B. subtilis expresses a single isoform. Sustained expression of both isoforms during 
vegetative and stationary growth suggests that both maintain active roles over the life cycle 
of C. difficile. Similar to B. subtilis, C. difficile expresses the ClpX and ClpC cochaperones, 
both of which exhibit high sequence identity to the B. subtilis variants (ClpX: 72% and 
ClpC: 60%). Comparatively, both ClpP1 and ClpP2 are highly similar to B. subtilis ClpP 
and there are no obvious differences between known regulatory domains (ClpP1: 74% and 
ClpP2: 63%). Interestingly, proteomic and transcriptomic studies suggest ClpP1, ClpX, 
and ClpC are present in purified C. difficile spores, while ClpP2 is absent. This suggests 
that ClpP1 plays an essential role in sporulation or germination and may interact with ClpX 
or ClpC. Given the parallels between sporulation in both organisms, we hypothesized that 
ClpP1 and ClpP2 influence sporulation in C. difficile, but that each isoform exhibits 
disparate roles. 
This chapter describes our initial phenotypic studies with clpP1, clpP2, and 
clpP1/clpP2 knockout mutants produced in collaboration with Dr. Jim Ballard’s 
laboratory. These mutants were generated using a novel CRISPR-Cas9 nickase system, and 
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these results represent the first application of this methodology. Each clpP mutant has been 
genomically sequenced to ensure no off-target mutations occurred, and that no significant 
mutations exist in laboratory-maintained strain of C. difficile 630.  The data presented 
herein demonstrate that 1) P1 mutants have lower sporulation efficiency, and severe 
morphological abnormalities during forespore engulfment; 2) P2 mutants hypersporulate 
but have little morphological differences overall; 3) P1P2 mutants fail to sporulate; and 
4) all three mutants exhibit decreased levels of cytotoxicity. Bright-field, fluorescence, and 
transmission electron microscopy reveals the P1P2 mutant to form multiple small-
compartments that are engulfed to begin the forespore lifecycle, yet fail to mature or 
become viable. Lastly, we propose a working model of sporulation that incorporates 
overlapping and distinctive roles for ClpP1 and ClpP2 in regulating sporulation. 
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3.3 Results 
3.3.1 clpP mutants are less cytotoxic, P1 is sensitive to heat-shock 
 
Figure 3.1 Growth profiles for clpP mutants and cytotoxicity TcdB titer assay  
(A) C. difficile were grown anaerobically at 37 °C (top) and 42 °C (bottom) and OD600 
was continually monitored over 36h. (B) Natively purified TcdB from C. difficile 630 was 
used to titer relative TcdB toxin levels against CHO (top) and Caco-2 (bottom) mammalian 
cells (WT red, P1 green, P2 blue, P1P2 orange, for all figures). 
 
WT and mutant clpP strains exhibit similar growth profiles in supplemented Brain 
Heart Infusion (BHIS) media at 37 °C (Figure 3.1A, top). The P1 mutant was unable to 
replicate under heat-shock conditions at 42 °C, while P2 grew similarly to the WT 
(Figure 3.1A, below). Despite P1 growth inhibition at the elevated temperature, the 
P1P2 mutant was able to replicate under heat-shock conditions, albeit at a substantially 
slower growth-rate. In minimal-defined media, all mutants deviated from WT growth under 
heat-shock conditions (Appendix B.1). P1 replicates minimally before entering 
stationary growth, while P2 and P1P2 grow exponentially before shifting to the 
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stationary phase at different time points. None of the mutants significantly differed in 
motility (Appendix B.2). 
The uncoupled activity of ClpP1 and ClpP2 described in Chapter 2 led us to 
anticipate disparate roles in biology, manifesting phenotypes linked to their respective 
regulatory function. In a recent study, Baker et al. suggest Pseudomonas aeruginosa ClpP1 
and ClpP2 exhibit separate roles in virulence.17 Though a Gram-negative organism, the 
results demonstrate that each ClpP isoform maintains specialized functionality and are 
differentially expressed between exponential and stationary growth. ClpP1 plays an 
important role in toxin production, while ClpP2 influences late-stage adhesion and 
microcolony formation. We anticipated a similar outcome in C. difficile and began by 
examining cytotoxicity in the clpP mutants. In a TcdB toxin titer assay using Chinese 
Hampster Ovarian (CHO) (Figure 3.1A, top) and Caco-2 endothelial cells (Figure 3.1A, 
bottom), all mutants exhibited one to two-fold lower cytotoxicity in comparison to the WT. 
P1 and P2 exhibit similarly reduced cytotoxicity levels, while P1P2 is the least toxic 
mutant. Here we observed equal contributions to cytotoxicity from each isoform deletion, 
with an additive effect being observed in the P1P2 mutant. Therefore, either ClpP isoform 
is likely sufficient to rescue toxin production and/or secretion.  
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3.3.2 Sporulation phenotypes differ significantly between mutants 
 
Figure 3.2 Bright field microscopy and semi-quantitative analysis shows varied 
sporulation in P1 and P2 
(A) Bright field microscopy images were taken with a DP8 Olympus Camera (Ph3, 100x), 
of each strain after 20-23 h of growth on 70:30 plate media. Cells were embedded into 1% 
agarose and sealed with a coverslip surrounded in vacuum grease. Vegetative C. difficile 
are phase-dark rods, while spores appear phase-bright. Scale bar = 5 µm. (B) Areas of 
significantly high cell density were counted under high phase-contrast, which show 
vegetative cells as phase-dark rods, and spores as small phase-bright ovals. Apparent 
sporulation efficiency was calculated by (# phase-bright spores / # vegetative cell) x 100%.  
 
Cultures of each mutant entering exponential growth were plated on 70:30 (70% 
BHIS and 30% sporulation media culture (SMC)) media and incubated for ~20 h prior to 
examination via phase microscopy. 70:30 plate media is generally believed to enhance C. 
difficile sporulation, and yields more reproducible spore counts.18 Samples were examined 
via bright field microscopy to assess apparent sporulation efficiencies (ASE) for each 
mutant, calculated by dividing the total number of phase-bright spores by the total number 
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of vegetative cells (Figure 3.2A and B). This is a qualitative method, which makes broad 
conclusions about the sporulation efficiency being observed and is simply suggestive as 
entities other than spores can appear phase-bright. P1 produced phase-bright spores with 
approximately 2.0% ASE, while P2 exhibited hypersporulation, and was 10.3% more 
efficient than the WT. Surprisingly, we found the ASE for P1P2 was <0.10%, 
significantly lower than the WT (Figure 3.2C). 
To qualitatively measure clpP mutant sporulation, samples were taken after ~22 h 
incubation from 70:30 plates. Half of the sample is initially struck out on BHIS media 
supplemented with taurocholate to enumerate vegetative cells and spores19–21 to get a total 
cell count. The other half is heat-treated to kill vegetative cells, while retaining mature 
spores that are heat-tolerant. Dividing the number of spores enumerated by the total number 
of cells provides the sporulation efficiency. This method provides more robust results that 
are highly repeatable, as it excludes counting immature spores that also appear phase-
bright. After heat-treatment, P1 sporulation efficiency was found to be 69% lower than 
the WT, suggesting that spores produced in P1 are more susceptible to heat-inactivation 
(Figure 3.3A). P2 sporulation efficiency did not significantly differ from WT (Figure 
3.3A), despite apparent hypersporulation when quantified via bright field microscopy. 
Spores were not observed in P1P2 after heat-treatment, which suggests any spores 
observed via bright field microscopy were immature. From these results, we determined 
that sporulation was severely inhibited in P1 and P1P2, while the P2 mutant produced 
approximately the same quantity of heat-tolerant spores as the WT.  
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Interestingly, if sporulation efficiency was assessed in BHIS broth rather than 70:30 
plate media, P1 and P2 fail to produce spores above the limit of detection (1 x 102 CFU) 
after 24 h of incubation. As such, P1 and P2 initially produce less spores than the WT 
in BHIS broth (Figure 3.3B). However, both mutants will produce similar quantities of 
mature spores as the WT, given >72 h incubation, which suggests the rate of sporulation 
lags in clpP mutants. P1P2 was not found to sporulate in BHIS broth, despite incubation 
to endpoint sporulation at 6 d. It is generally believed that C. difficile sporulation is 
complete at the 6 d timepoint (>144 h).22 P1P2 spore enumeration at 6 d was performed 
via heat-treatment and ethanol treatment to differentiate between heat and ethanol 
susceptibility. Spore outgrowth was not observed in either method at endpoint incubation 
for P1P2. 
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Figure 3.3 Sporulation efficiency and rate aberrations in clpP mutants  
(A) Sporulation efficiency was measured after sporangia heat-inactivation on 70:30 plate 
media. (B) Rates of sporulation in BHIS broth for WT and clpP mutants. (L.O.D. Limit of 
detection, 1 x 102 CFU) (C) Table of sporulation efficiency experimental results. (n.d. not 
determined) 
 
Notably, bright field microscopy analysis of P1P2 revealed frequent elongated 
cell phenotypes, with multiple phase-bright spore-like structures populating the length of 
the cell (Appendix B.3). These elongated cells were significantly longer, averaging 
approximately 521 µm while normal vegetative C. difficile cells are 4-5 µm. It should be 
noted that while elongated cells were observed frequently, not all exhibited multiple phase 
bright regions. Of those that did, phase-bright spore-like structures were present 
asymmetrically, and stochastically spaced. These observations indicate that P1P2 may be 
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able to initiate sporulation but fails to coordinate the initial forespore development or 
engulfment. 
To vividly illustrate differences in forespore development and sporulation, we 
performed fluorescence microscopy with samples of sporulating cultures. Samples were 
propagated in SMC media for ~23 h to sufficiently induce sporulation prior to harvesting.23 
Hoescht 33342 (referred to hereafter as Hoescht), which penetrates vegetative cells and 
immature spores, was used to stain nuclear DNA (blue). Samples were harvested and 
immobilized on 1% agarose pads on glass slides mixed with the lipophilic dye FM 4-64 
(red), which stains bacterial cell walls and spore coats bright red. Mature spores are 
expected to appear red, as they exclude Hoescht and only retain FM 4-64, providing 
significant contrast between forespores and mature spores.24  
 
 
Figure 3.4 Sporulation in C. difficile  
Sporulation in C. difficile occurs via a highly conserved process across spore-forming 
bacteria, that generally begins with the activation of Spo0A to initiate asymmetric division 
and begin sporulation. A small compartment containing compacted genomic material will 
be shed, then rapidly engulfed in a phagocytic-like mechanism. Activation of Spo0A will 
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inhibit SpoIIAB (anti-σF), leading to σF activation that localizes to the pre-forespore prior 
to engulfment completion. σF coordinates initial forespore development, which will then 
activate σE upon engulfment to begin forespore development and activate σG when the 
forespore has been fully engulfed. Image adapted and modified with permission. 
 
In WT cells, the mature forespore is localized to one pole and brightly fluoresces 
with FM 4-64 stain. P1 forespore engulfment is delocalized and overlaps the outer 
membrane, which may indicate defective or delayed engulfment (Figure 3.5, P1). The 
intracellular location of P2 forespores are varied, which may result in premature spore 
release (Figure 3.5, P2). Elongated P1P2 mutants formed multiple lipid-dense particles 
throughout the length of the cell which appeared spore-like (Figure 3.5, merged P1P2). 
The abnormal forespores in P1P2 were also found to delocalize across the cell wall, 
suggesting deficient or stalled engulfment. Overall, P1P2 appears to lack coordinated 
asymmetric division during the initial stages of sporulation, resulting in: 1) abnormal 
septation, 2) multiple apparent forespores throughout the elongated cell, 3) unsuccessful 
engulfment. To structurally interrogate sporulation and the spores themselves, we decided 
to perform transmission electron microscopy (TEM) on sporulated cultures. 
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Figure 3.5 Forespore development in sporulating cultures imaged with fluorescent 
microscopy  
Sporulating cultures of C. difficile and clpP mutants were obtained with a Zeiss Axiovert 
200m at 63x magnification under oil-immersion. A differential contrast filter was used to 
obtain phased bright-field images. Cells were stained with Hoescht (blue channel) and FM 
4-64 (red channel) to differentiate between DNA and bacterial cell wall, respectively. 0.1 
µm Z-stacked images were obtained in red and blue channels to aid focusing and reduce 
the background noise. Individual color channels were merged into a composite and 
normalized with ImageJ.25 Scale bar represents 1 µm. 
 
3.3.3 Loss of ClpP function results in morphological distortions during spore development 
Successfully engulfed forespores were observed in the P1 mutant that were 
morphologically similar to WT and absent of obvious structural abnormalities (Figure 3.6). 
However, P1 also exhibited severe morphological abnormalities during what appears to 
be forespore engulfment (Figure 3.7A). Nearly half (47.9%) of sporulating cells appeared 
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to have stalled during forespore engulfment, and of those that were successfully engulfed 
30.9% displayed distorted phenotypes (Figure 3.7B). Though we cannot state this 
definitively in thin-section TEM without Z-stack analysis, as cells are oriented over one 
another. Interestingly, some possessed phase-dark spots flanking the forespore (Figure 
3.7A). Perhaps this is compressed outer cell membrane or an aggregation of the engulfment 
machinery, but this is purely speculative. Together, these results hint towards P1 possibly 
generating a stalled engulfment phenotype, but this evidence alone is not enough to 
conclusively suggest so.  
 
 
 
Figure 3.6 Typical cellular morphology of each strain in sporulating cultures  
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P1 and P2 produced characteristic forespore morphologies, while no spores were 
observed in P1P2 cells. White arrows denote light-colored areas between the spore coats, 
which appear to be the cortex. Black triangles indicate forespore coat proteins. Scale bars 
represent 1 µm. See Appendix B.4-B.11 for overview TEM images. 
 
Loss of ClpP2 function did not correlate with an increased frequency of apparent 
sporulation errors when compared to the WT (Figure 3.6). However, P2 mutants 
produced an abundance of small vesicles that are regularly dispersed throughout each thin 
section sample that was analyzed (Appendix B.8). These appear to be small compartments 
that are released coinciding with the initiation of sporulation, which are subsequently 
engulfed to form the forespore. Similarly, an abundance of small compartments was 
observed throughout P1P2 in TEM analysis. P1P2 mutants attempted engulfment 
though no spores or intracellular structures containing a forespore were observed, 
suggesting loss of both ClpP1 and ClpP2 function renders C. difficile unable to complete 
engulfment.  
 
Figure 3.7 Representative TEM images of apparent P1 morphological abnormalities  
(A) TEM images of P1 depict irregular morphologies related to sporulation. Scale bars 
represent 1 µm (B) Morphological abnormalities were quantified by counting at least 100 
cells per biological replicate.  
 
In order to determine whether the spore ultrastructure was impacted by loss of ClpP 
function, spores were isolated and purified from sporulating cultures.26 Mature C. difficile 
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spores are composed of several distinct layers as shown in Figure 3.8A. No attached 
exosporium was observed in P1 and P2 spores, which rarely remain intact during spore 
purification and TEM preparation.27 P1 and P2 spores were not found to significantly 
differ in overall spore ultrastructure, forming characteristic spore coat layers and dense 
cortex (Figure 3.8B). P1P2 formed circular structures similar in shape and size to spores 
isolated in the WT but lacked any structural features of a typical spore (Figure 3.8A and 
B).  
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Figure 3.8 P1 and P2 produce mature spores, P1P2 spores are immature  
(A) Mature spore structure (B) TEM analysis of purified spores from each strain. The coat 
proteins and denseness of the core itself in mature spores will often prohibit total resin 
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penetration, causing the core to appear hollow. P1 and P2 are able to produce mature 
spores, while P1P2 produces porous vesicles. Scale bar represents 100 nm. 
 
 P1P2 appears to be unable to complete engulfment to produce a forespore, which 
precludes spore formation. P1P2 sporulation efficiency at endpoint sporulation was 0%, 
failing to produce mature spores which could be enumerated after heat-treatment. Taken 
together with the results from our TEM analysis, it appears total loss of ClpP function in 
C. difficile generates an asporogenic phenotype. P1 also struggles to complete 
engulfment, while P2 appears to produce mature spores similarly to WT. Although P1 
can eventually complete engulfment, P1P2 is unable to do so. Taken together this 
suggests that ClpP2 may regulate engulfment directly or indirectly through an unknown 
mechanism. P2 mutants produce an abundance of small vesicles similar to P1P2, 
otherwise they are phenotypically similar to WT. This suggests differentiated roles for each 
ClpP isoform at the initiation of engulfment, which overlaps with engulfment completion. 
To determine a possible reason for the errors during engulfment we examined the relative 
expression of known sporulation regulators in C. difficile. 
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3.3.4 Sigma factor expression is dramatically reduced in P1P2 
 
Figure 3.9 Western blot analysis of sigma-factors that control sporulation in C. 
difficile  
(A) Samples at exponential phase were plated onto 70:30 media to induce sporulation over 
44 h. Molecular weights (MW) are shown to the left (kDa) while each corresponding 
sporulation factor is to the right. Asterisk indicates an off-target band which has previously 
been observed.28 (B) Relative intensities of individual bands when compared against WT. 
 
Spo0A is the master sporulation regulator in C. difficile and is highly conserved 
across spore-forming Gram-positive organisms.1,29–31 Spo0A regulates ~75% of the 
sporulation-related genes in C. difficile, and ultimately controls the initiation of the 
sporulation cascade.8 Loss of Spo0A function renders C. difficile unable to express any of 
the -factors necessary to orchestrate sporulation, precluding sporulation.28 Spo0A is 
overexpressed in all mutants, which may be indicative an attempt to rescue sporulation or 
a general stress response. Alternatively, ClpP may regulate systems that inhibit or promote 
sporulation (e.g., CodY is a known substrate of ClpCP), thus ClpP may indirectly 
participate in sporulation regulation. -factors present in the mother cell and forespore are 
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activated during specific phases of sporulation after Spo0A is activated by phosphorylation 
(Figure 3.4). F and G, which are confined to the forespore, are activated following 
asymmetric division. E and K reside in the mother cell and coordinate expression with 
other forespore -factors via cell-cell communication. Upon phosphorylation, Spo0A 
activates σF immediately following asymmetric division to coordinate early stages of 
sporulation. The ΔP1 and ΔP2 mutants exhibit slightly elevated levels of F to the WT, 
while ΔP1P2 F expression is lower than WT expression (Figure 3.9). E activation 
follows soon after F to direct forespore development in the mother cell. The ΔP1 mutant 
significantly overexpresses E, while ΔP2 exhibits increased expression compared to the 
ΔP1P2 mutant but less than ΔP1, and displays a similar phenotype as previously reported 
in sigG mutants.28 G expression is upregulated following the completion of engulfment, 
and both ΔP1 and ΔP2 mutants overexpressed G, while the ΔP1P2 expression is similar 
to the WT. G activates K, concluding engulfment, and only occurs in the presence of 
expressed SpoIIIA-operon proteins. All three mutants express similar levels of K, whose 
expression does not rely upon activation of a former -factor.  
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Figure 3.10 Sequence of sigma factor activations and sporulation processes 
Sigma factors are activated following Spo0A phosphorylation which initiates sporulation 
1) F is activated and upregulates SpoIIP and SpoIIQ which signals the start of engulfment. 
Simultaneously Pro-E is processed to E in the mother cell, which starts organizing initial 
forespore development factors 2) E upregulates SpoIIIA which also signals engulfment 3) 
G activity is stimulated by F, which typically coincides with completion of engulfment 
4) K activity is stimulated by E, which then upregulates expression of coat proteins and 
coincides with mother cell lysis and subsequent spore release.  
 
SpoIIP is part of the “DPM” complex comprised of SpoIID, SpoIIP, and SpoIIM, 
which functions to initiate and complete engulfment during sporulation.32–34 Successful 
engulfment requires the steady degradation of mother cell wall composed of peptidoglycan 
and proceeds via a “zipper-like” mechanism.32 SpoIID engulfment machinery “pulls” the 
mother cell around the forespore, while SpoIIP degrades peptidoglycan coordinated by the 
scaffolding protein SpoIIM, to enclose the forespore within the germ cell wall and form a 
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layer of the outer spore coat. Loss of SpoIID, SpoIIP, or SpoIIM will trigger the engulfment 
vesicle to collapse, and push the small compartment outward. P1 and ΔP1P2 lack SpoIIP 
expression, offering a possible explanation as to why the possibly defective forespore 
engulfment occurs in the former, and inhibited in the latter.  
 
3.4 Discussion 
 
Figure 3.11 Venn-diagram summary conclusion 
Summary of the overall conclusion drawn from this work. P1 frequently fails to engulf 
the forespore, producing less spores overall. P2 Is similar to WT in spore efficiency, but 
appears to make more pre-spore structures. P1P2 is unable to produce mature spores. 
 
The work described in this chapter builds upon work described in Chapter 2, which 
describes the biochemical characterization of recombinant ClpP1 and ClpP2 in vitro. Our 
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results from this study broadly reveal differences in sporulation and cytotoxicity 
phenotypes for all of the ClpP mutants generated. We to successfully produced knockout 
mutants of clpP1, clpP2, and the dual clpP1/clpP2. Our attempts at P1P2 
complementation have failed thus far due to the inherent design of the CRISPR/Cas9 
mutagenesis system employed. Complements have been produced for both clpP1 and 
clpP2, but we have had difficulty replicating experimental results to demonstrate reversion 
to WT behavior. We believe this is likely due to the requirement of thiamphenicol within 
the culture media during complementation growth. This is needed to select for C. difficile 
that retains the complement plasmid encoding thiamphenicol resistance. Thiamphenicol 
degrades rapidly at elevated temperatures and we speculate that as the concentration 
decreases, C. difficile rejects the plasmid and reverts back to the mutant phenotype.35  
 To address this issue, we have pivoted to a new strategy, which will incorporate 
the CRISPR/Cas9 machinery into the C. difficile chromosome, allowing tunable genetic 
silencing via the introduction of targeting vectors. The targeting vectors will contain our 
guide sequence (gRNA) and be integrated chromosomally via homologous recombination. 
In this manner, the CRISPR/Cas9 machinery will be natively expressed at a basal rate and 
integration of the targeting vector to the CRISPR/Cas9 operon will ensure our gRNA will 
be produced. Therefore, it is not necessary to retain the targeting vector as the point 
mutation will be permanent. Our current vector contains the CRIPSR/Cas9 machinery, 
thiamphenicol resistance, gRNA, and homologous recombination region resulting in a 
>10kb plasmid. This reduces the likelihood it is retained during normal binary division. 
Integration to the chromosome will lower the size of the plasmid to 2 kb, significantly 
increasing the likelihood complementation will be successful. As stated earlier, whole 
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genome sequencing was performed on our WT strain of C. difficile 630 along with 
biological triplicates of each mutant. No off-target mutations were observed, and no 
mutations were present in any gene known to impact sporulation or virulence prior to or 
after CRISPR/Cas9 mutagenesis. Thus, we are confident that an alteration in experimental 
approach will provide a means to overcome the short-comings of the previous strategy. 
Loss of either ClpP1 or ClpP2 equally decreases cytotoxicity and loss of both 
homologs additively reduce cytotoxicity against both CHO and Caco-2 cell lines. Growth 
profiles for all mutants vary in response to elevated temperature, with significant 
differences observed when grown in a defined minimal medium,37,38 particularly under 
heat-shock. Heat-treating cells reveals a reduced sporulation efficiency for P1, 69% lower 
than the WT. Spores produced by P1 are more susceptible to heat-inactivation, in contrast 
to P2 which possess a sporulation efficiency similar to the WT. This differs from spore 
quantitation results produced via bright field microscopy that suggest P2 may produce 
spores that are immature and therefore heat-intolerant. We failed to observe any P1P2 
spores post heat-treatment, indicating that any spores observed via bright field microscopy 
were immature or were phase-bright artifacts. From these results, we determined that 
sporulation is substantially inhibited in P1, and unlikely to occur in P1P2. P2 
maintained similar levels of sporulation to the WT. 
P1 forespore engulfment overlaps between the forespore and cell wall, which was 
not frequently observed in WT, which may be indicative of defective engulfment. The 
intracellular location of P2 forespores varies, which may allow for the forespore to 
disengage or prematurely release from the mother cell. The elongated P1P2 mutant 
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commonly forms multiple brightly staining spore-like structures throughout the length of 
the cell. The brightly stained vesicles could also be septa, repetitively forming and dividing, 
and so on to elongate the cell. Hoescht stain trails one of the lipid-dense areas, suggesting 
DNA condensation towards that point which is a precursor to asymmetric division. These 
results demonstrate a lack of coordinated asymmetric division, and irregular sporulation 
initiation occurring towards the cell poles. 
TEM results demonstrated the ability of P1 and P2 to sporulate, while P1P2 
failed to produce spores or forespores. P1 is able to overcome what appears to be delayed 
or stalled engulfment, though phenotypic abnormalities seem to arise during sporulation, 
to produce mature spores that are morphologically similar to WT. P2 mutants do not show 
an abnormal sporulation phenotype. Instead, loss of ClpP2 function leads to overproduction 
of small vesicles also apparent in P1P2 mutants. P1P2 produces circular vesicles similar 
in size to mature spores, though no characteristic spore layers form. Purified spore samples 
analyzed via TEM also show fully mature spores produce by P1 and P2 mutants, 
whereas the P1P2 mutant produces only the pseudo-spore husks. 
Western blot results reveal that P1 and P2 overexpress F, which has previously 
been observed in E mutants that exhibit a stalled sporulation phenotype.16,28 E is highly 
overexpressed in P1, and slightly less so in P2, signaling activation of sporulation 
factors present in the mother cell that coincide with successful engulfment. In this manner, 
E is more strongly overexpressed in P1, which may indicate an attempt to rescue 
engulfment. Recent studies have demonstrated that E is required for engulfment 
machinery expression, offering an explanation for the P1 mutant exhibiting increased 
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evidence of stalling during this phase of sporulation.34,36 However, E is dispensable in G 
activation, and G can be activated without the presence of E or F,28 suggesting that ClpP1 
and ClpP2 both play a role in indirectly regulating G expression.  
SpoIIP expression is abolished in P1 mutants, but significantly overexpressed in 
P2. F has been shown to positively regulate SpoIIP expression and subsequent SpoIIP 
processing, which is absent in P1 despite increased SigF expression. P2 processes 
SpoIIP and exhibits sporulation efficiency similar to the WT, agreeing with previous 
reports that SpoIIP is required for engulfment and sporulation.32 SpoIIP is processed to the 
cleaved form in the P1P2 mutant, which cannot form mature spores. This is contrary to 
P1 mutants, which express virtually no forms of SpoIIP but still form viable spores. From 
this, it seems ClpP1 function is necessary for efficient SpoIIP processing, though loss of 
ClpP1 function does not always arrest sporulation. Loss of ClpP1 and ClpP2 function 
restores SpoIIP processing to form cleaved SpoIIP but cannot form mature spores 
suggesting alternate regulatory roles for ClpP1 and ClpP2.  
No spores or engulfed forespores are observed in P1P2 mutants, which suggests 
that cooperativity may exist between ClpP1 and ClpP2 in order to complete sporulation. 
Perhaps in vivo, a heteromeric ClpP1/ClpP2 complex is formed that cooperates with 
sporulation regulatory factors. Previously, we were unable to produce a heteromeric 
ClpP1/ClpP2 complex in vitro using recombinant protein, but we are cognizant that 
recombinant approaches fail to accurately mimic the complex nature of the cell and thus 
does not rule out heterocomplex formation in vivo. Other intracellular factors may be 
involved with altering ClpP1 or ClpP2 in vivo to promote heterocomplex formation. 
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However, our results point to ClpP1 and ClpP2 maintaining distinct roles in regulating 
sporulation, with loss of both isoforms resulting in the inhibition of spore formation. In this 
manner, this work shows the therapeutic potential and biological significance for inhibition 
of ClpP in C. difficile. Inhibiting ClpP could reduce or even abolish sporulation, which 
would halt the transmission cycle, disabling CDI transmission. It follows that ClpP is a 
potentially druggable target in C. difficile that offers new inroads for developing drugs that 
act on novel pathways. 
3.5 Materials and Methods 
3.5.1 Bacterial strains and growth conditions 
 630 was used as the model strain of Clostridium difficile in all experiments 
described herein (ATCC: BAA-1382-FZ). Frozen stocks were grown anaerobically at       
37 C in a COY vinyl anaerobic chamber which maintained an atmosphere of 85% N2, 
10% H2, and 5% CO2. C. difficile was routinely cultured in Brain Heart Infusion media, 
supplemented with yeast extract (BHIS). Cefoxitin (8 g/mL), thiamphenicol (20 g/mL), 
taurocholate (0.1% w/v), and kanamycin (50 g/mL) were used as needed in conjugation 
complementation experiments during CRISPR/Cas9 mutagenesis.  
3.5.2 clpP mutant generation 
The methodology describing the generation of clpP mutants in C. difficile is novel 
and currently unpublished, and as such some specific details will be omitted or described 
vaguely on purpose. The pMTL84151 plasmid was utilized as the vector to introduce the 
CRISPR/Cas9 machinery along with guide sequence for the ClpP1 and ClpP2 mutants 
(Appendix B.13). The ClpP1 and ClpP2 serine proteases of Clostridium difficile 630 were 
targeted for genetic alteration via CRISPR/Cas9 mutagenesis, in a manner similar to 
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previously described methodologies.37 Both involved the addition of an NheI restriction 
site upon homology directed repair from the donor template sequence on the vector. This 
change resulted in a stop codon being formed at the 13th residue of ClpP1 (GGA → TGA) 
and the 12th of ClpP2 (CAA → TAA). After vector construction, conjugation with 
donor E. coli, and five passages under selective pressure the respective cultures were plated 
and screened via PCR followed by NheI restriction digestion. Sanger sequencing further 
confirmed the accuracy of the desired genetic alteration. Additionally, whole genome 
resequencing was conducted to confirm that no off-target mutations occurred. 
Single complement mutants were constructed by inserting the pMTL84151 plasmid 
back into each ClpP mutant. Each complement was constructed by inserting clpP1 + 100bp 
upstream, or clpP2 + 100bp upstream into the lacZ operon in the pMTL84151 plasmid. To 
ensure the promoter region was maintained, the entire gene plus 100bp upstream of clpP1 
or clpP2 was performed. In this manner, both of the single complementation vectors were 
made and then introduced into C. difficile 630 via conjugation.  
3.5.3 Genomic sequencing 
Frozen stocks of C. difficile maintained by the Ballard laboratory were struck onto 
BHIS agar plates supplemented with taurocholate along with the ATCC reference strain 
and clpP mutants. Individual colonies were picked for each strain to inoculate ~5 mL of 
BHIS broth and allowed to grow for 12 h. Genomic DNA was isolated from each culture 
using the GenElute Bacterial Genomic DNA kit (Thermo) and purified with the Zymo 
Genomic DNA Clean and Concentrator kit (Zymo). DNA samples were sent to the 
Oklahoma Medical Research Foundation for DNA library preparation and Next Generation 
sequencing performed with a MiSeqV1. Data was processed in Geneous. 
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3.5.4 Growth curves 
~5mL of BHIS was inoculated with freezer stocks of WT and the clpP mutants, and 
allowed to grow overnight. Overnight cultures were back diluted 1:1,000 and allowed to 
reach exponential growth (OD600 = 0.4 – 0.5) before 1:10,000 dilution in BHIS, with 10 
300 L aliquots of each strain distributed into Bioscreen C honeycomb plates. The plates 
were sealed with vacuum grease and placed into a Bioscreener C plate reader, and OD600 
measurements were taken every 30 minutes for 36 – 48 h at 37 C with no shaking. All 
readings have been normalized to the media control (background subtracted). 
3.5.5 Cytotoxicity titer assay 
72 h cultures of the WT and clpP mutants were pelleted (3000x rcf, 15 minutes) in 
order to extract the supernatant. The supernatants were 0.2 m syringe filtered and serially 
diluted in the appropriate mammalian cell medium accordingly. Filtering the supernatant 
removed the bacteria, but retains the toxins TcdA and TcdB. 
All mammalian cell cultures were grown in cell culture treated plastics, in a 
humidified incubator at 37 C with 5% CO2. Caco-2 and CHO cells were cultured as 
recommended by ATCC, with Eagles Defined Medium (EMM) and F-12K medium, both 
supplemented with 10% Fetal bovine serum (FBS). Cell cultures were trypsinized once 
they had reached ~80% confluency, and equal volumes of media were added to neutralize 
the trypsin. Detached cells were then harvested by centrifugation (100x rcf, 15 minutes) 
and resuspended in appropriate media. 100 L aliquots (5 x 105 cell density) were used to 
seed 96-well plates and were allowed to grow overnight. Once cells had reached 60-70% 
confluency, the media was aspirated and serially diluted supernatant from each strain was 
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added across triplicate wells to the seeded 96-well plates. Plates were then incubated with 
the supernatant for 18h before cell viability was assessed via Cell Counting Kit-8 (CCK-8, 
Dojindo) according to the manufacturer. 
3.5.6 Plate-based sporulation 
 Plate-based sporulation was performed as previously described,38 but will be 
discussed here briefly. Frozen glycerol stocks of WT and clpP mutants were used to 
inoculate starter cultures of ~5 mL BHIS and allowed to grow overnight. Overnight culture 
was back-diluted 1:20 into ~2 mL of BHIS and allowed to reach exponential phase growth 
at ~0.4 OD600. 100 L of exponential phase culture was used to inoculate 70:30 plates 
(70% BHIS, 30% SMC) to lawn the bacteria. Sporulation was induced for ~20 – 22 h, 
before harvesting and resuspending in PBS. These samples were then used for downstream 
applications. 
3.5.7 Liquid-culture sporulation 
 Frozen glycerol stocks were used to inoculate ~5 mL of BHIS, and allowed to grow 
overnight before 1:200 back-dilution into SMC broth.38 Sporulation was allowed to 
continue for 20 - 24 h before they were prepared for fluorescent microscopy analysis. 
3.5.8 Sporulation efficiency assay 
 Sporulation efficiency was determined as previously described.39 Plate-based spore 
samples were thoroughly resuspended in PBS with 10 L of each sample was then serially 
diluted and plated on BHIS supplemented with 0.1% taurocholate in triplicate for total cell 
count. The original resuspended samples were then incubated at 70 C for 30 minutes, 
briefly vortexed every 10 minutes, and then 10 L of each sample was plated onto BHIS 
media in triplicate to quantify mature spores. By comparing the quantity of spores to the 
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total cell count, the sporulation efficiency can be calculated. Statistical significance was 
obtained by One-way ANOVA and Tukey test. 
Otherwise, ASE can be quantified by visually counting spores and vegetative cells 
via differential contrast or phase contrast microscopy. Comparing vegetative cell counts to 
spore counts yields the ASE.  
3.5.9 Microscopy analysis 
 Liquid-based spore samples from each strain were back-diluted 1:10 in BHIS media 
and incubated with 3 - 4 drops of Hoescht 33342 (15 g/mL) for 1 h at 37 C anaerobically. 
6 L of Hoescht stained samples were then immobilized microscope slides with 1% 
agarose pads that contained 1% (w/v) FM 4-64. The agarose pads were then sealed with 
coverslips. Bright field and fluorescence microscopy were then performed using a Zeiss 
Axiovert 200m at 63x magnification under oil-immersion, imaged with a CCD AxioCam. 
Some phased images were obtained with a DP8 Olympus Camera (Ph3, 100x) where 
described. A differential contrast filter was used to obtain phased bright-field images. 0.1 
µm Z-stacked images were obtained in red and blue channels to aid focusing and reduce 
background noise. Individual color channels were merged into a composite image and 
normalized with ImageJ.25 
3.5.10 Transmission Electron Microscopy 
 TEM sample preparation was performed by OMRF personnel, as described herein. 
Spores were fixed with 4% Paraformaldehyde (EM grade), 2.5% Gluteraldehyde (EM 
grade), in 0.2M Sodium Cacodylate buffer for 1 day at 4 ⁰C. Samples were then post fixed 
for 60 minutes in 1% Osmium tetroxide (OsO4) in 0.2M Sodium Cacodylate, and rinsed 
three times for five minutes each in 0.2M Sodium Cacodylate buffer. The samples were 
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stored in 0.2M Sodium Cacodylate buffer overnight on a rocker at room temperature. The 
spores were then dehydrated in a graded ethanol series. The ethanol gradient was as 
follows; 50%, 60%, 75%, 85%, 95%, 100%. The spores were in each concentration for 15 
minutes on a rocker. Then the samples had two 15-minute treatments in 100% Propylene 
Oxide. Following dehydration, the samples were infiltrated in a graded Epon/Araldite 
(EMS) resin/Propylene Oxide series (1:3, 1:1, 3:1) for 60 minutes, overnight, and 120 
minutes the next day respectfully. The spores were further infiltrated with pure resin for 45 
minutes, 90 minutes, and then overnight. The samples were then embedded in resin plus 
BDMA (accelerator) and polymerized at 60 °C for 48 hours. Ultrathin sections were stained 
with Sato’s Lead and Saturated Uranyl Acetate in 50% methanol before viewing on a 
Hitachi H7600 Transmission Electron Microscope. At least 200 cells were counted for 
quantification. 
3.5.11 Western blot analysis 
 Plate-based spore samples (~40 h sporulation) were pelleted and resuspended in 1 
mL of Western Blot buffer (8M Urea, 10mM -mercaptoethanol).  Samples were then 
mixed 1:1 with 2x SDS-PAGE loading buffer (Bio-Rad), and heated at 100 ⁰C for 10 
minutes before centrifugation at 15,000x rcf for 8 minutes. 5 µL of each sample was then 
loaded onto 4-20% TGX Bis-Tris SDS-PAGE gradient gels (Bio-Rad) and resolved via 
electrophoresis until the dye front had migrated off the gel-front. The samples were then 
transferred onto Turbo-Blot PVDF membranes (Bio-Rad) and blocked with 5% non-fat 
milk in Tris-Buffered Saline with 0.1% (v/v) Tween-20 (TBST) for 1 h at room 
temperature. All antibodies were provided by Dr. Aimee Shen (Tufts) as a generous gift, 
and were obtained as described elsewhere.32 The primary antibodies were diluted 1:2000 
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in 5% non-fat milk in TBST and used to blot the membranes for each protein for 18-20 h 
at 4 ⁰C while rocked. The membranes were washed and then incubated with anti-rabbit and 
anti-mouse (Spo0A primary antibody was mouse derived, all others are rabbit-derived) 
horseradish peroxide (HRP) secondary antibodies, and were then diluted 1:2000 in 5% 
non-fat milk in TBST. Membranes were then incubated with secondary antibody for 1 h, 
washed, and treated with ECL Clarity substrate (Bio-Rad) as per the manufacturer 
description. Blots were then imaged with a Bio-Rad ChemiDoc MP Imaging System with 
automatic image correction applied. 
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Chapter 4  
Addressing ClpP Modulator Inefficiencies 
As discussed in Chapter 1 of this dissertation, ClpP represents a unique target for 
antibacterial discovery, as beneficial activity is observed via inhibition or activation of this 
protease (Figure 4.1). Activators stimulate ClpP and promote ATP-independent hydrolysis 
of intrinsically disordered intracellular proteins. Known activators of ClpP bind 
competitively to the cochaperone binding sites and thus operate via two mechanisms of 
action: 1) activating the ClpP protease and inducing unselective degradation; and 2) 
inhibiting the interaction of AAA+ cochaperones with ClpP, thus disrupting the ability of 
cochaperones to deliver natural substrates for degradation.1 Therefore, bacterial cells 
treated with ClpP activators suffer from self-digestion and a build-up of toxic substrates, 
resulting in a dual attack on microbes. Alternatively, inhibitors render ClpP proteolytically 
inactive by restricting conformational plasticity, or chemically inactivating the Ser-His-
Asp catalytic triad. While ClpP modulation has attracted serious interest from the 
antibacterial research community, little has been done to expand the arsenal of ClpP 
modulators.  Due to the liabilities of known modulators (discussed below), new 
chemotypes will be required in order to exploit ClpP clinically. In addition to our studies 
on the ClpP system in C. difficile, we have an ongoing interest in identifying new ClpP 
modulators and working to address the liabilities of known activators and/or inhibitors.  
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Figure 4.1 Therapeutically relevant orthogonal approaches to targeting ClpP 
 
4.1 Inhibitors 
Two classes of ClpP selective inhibitors, β-lactones and phenyl esters, have been 
identified (Figure 4.2).2 These inhibitors covalently modify the serine within the conserved 
catalytic triad to irreversibly halt proteolysis.3,4 β-lactones and phenyl esters exhibit unique 
activity profiles against different ClpP homologs. The β-lactones were the first ClpP 
selective inhibitors identified and SAR studies have produced efficacious analogs against 
S. aureus and M. tuberculosis.5–7 Although the β-lactones are effective at clearing S. aureus 
skin infections (sub-cutaneous injection) in mice, the utility of this class is limited by the 
susceptibility to hydrolysis in plasma (mouse = 3.7 ± 1.5 min, human = 4.7 ± 0.4 min).8–10 
Attempts to increase the stability of β-lactones have failed to provide pharmacological 
value, as potency suffers dramatically upon β-lactone replacement.4  
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In attempts to identify new ClpP inhibitory chemotypes, Sieber and colleagues 
screened a small molecule library and discovered the phenyl ester pharmacophore (Figure 
4.1).8 While this chemotype exhibits improved stability of the pharmacologically relevant 
acyl-enzyme complex (β-lactone: t1/2 = 5.0 h ± 0.4 h; phenyl ester: t1/2 = 8.2 h ± 0.8 h), no 
evidence of improved plasma stability is presented and translation of this chemotype into 
therapeutically relevant anti-virulence agents still represents a major hurdle.  
 
4.2 Activators 
4.2.1 Acyldepsipeptides (ADEPs) 
In 1985, acyldepsipeptide antibiotics (ADEPs) were isolated from Streptomyces 
hawaiiensis culture and were largely ignored until Heiki et al. determined that ADEPs bind 
and activate bacterial ClpP and elicit bacterial cell death.11,12 In a murine model ADEP1 
(A54556A) produced an 80% survival rate when provided as a treatment against a lethal 
challenge of S. aureus and E. faecalis, lowering bacterial loads in vital organs two to three-
fold versus the control. The mechanism of action was determined through biochemical 
means and the binding mode was revealed through the characterization of two ClpP:ADEP 
cocrystal structures, which showed that ADEPs bind to ClpP in a manner that mimics 
cochaperone binding.13–15 Cochaperones (e.g., ClpX) bind to ClpP via an I/FGL motif 
present towards the C-terminal end of each monomer, which interacts with the hydrophobic 
clefts between ClpP monomers.16,17 ADEPs bind competitively to the same monomeric 
interface, and trigger a conformational change that widens the axial pore of ClpP.1,14,15,18 
When activated, disordered proteins are able to diffuse into the proteolytic compartment to 
be degraded.  
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Eventually, studies revealed significant ADME drawbacks such as: poor solubility, 
poor bioavailability, and limited to no activity against Gram-negative bacteria.3 The first 
attempt to optimize ADEPs was undertaken by Hinzen et al., where it was found that 
removing conjugation of the acyl side-chain improved in vitro MIC activity assays and 
stability.20 Fluorination at the 3,5 positions of the phenyl ring coupled with alteration of 
the macrocyclic core to instill conformational rigidity were found to significantly improve 
in vitro activity (~160-fold). The resulting compound, ADEP4, was used in combination 
with rifampicin and erythromycin to eliminate spores, and rescue a mouse from a lethal 
challenge of MRSA.21 Further SAR studies on the ADEPs have produced >40 analogs, 
some of which exhibit impressive efficacy (≤0.0002 µg/mL) against Gram-positive 
pathogens (S. pneumoniae and E. faecalis).20,22–24 Unfortunately, pharmacokinetic (PK) 
detriments and the inability to surpass bacterial defense mechanisms continues to impede 
the clinical use of ADEPs.25   
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Figure 4.2 Current ClpP chemo-modulating scaffolds.  
 
4.2.2 Activators of Cylindrical Proteases (ACPs) 
A separate class of activators known as Activators of Cylindrical Proteases (ACPs) 
were found in a broad screen of >50,000 small molecules from multiple commercial library 
sources.26 Five ACPs (ACP1-ACP5) were found to stimulate B. subtilis ClpP to degrade 
an artificial substrate in vitro (i.e., FITC-casein) of which ACP1 was identified as the most 
potent. Therefore, chemical optimization proceeded with ACP1, resulting in the synthesis 
of ACP1a and ACP1b, which exhibited improved potency. MIC studies revealed that the 
chemical modification of this scaffold provided only a modest reduction in MIC between 
ACP1 and ACP1a/ACP1b of approximately 2-fold against N. meningitis. Notably, the 
combination of polymyxin-nonapeptide B (PMB) and ACP1b significantly lowered the 
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MIC against H. influenza. However, none of the ACPs tested approached MIC values 
reported for ADEP1 against any pathogen tested.  
The binding mode of ACPs has not been determined, but rather suggested through 
mutational and computational studies and by ACPs’ ability to prevent GFP-ssrA 
degradation in a ClpXP-mediated degradation assay. As observed with ADEPs,27 when 
ClpP is pre-treated with ACPs, ClpX is unable to translocate a GFP-ssrA substrate into the 
ClpP proteolytic chamber, thus inhibiting degradation. This is most likely due to ACP 
binding in the same clefts that ClpX interacts with in order to associate with ClpP for 
targeted proteolysis. Physical evidence of ACP binding was provided via isothermal 
titration calorimetry. In silico binding studies suggest that ACPs bind in the northern or 
southern clefts close to the N-termini of ClpP monomers in a manner similar to ADEP. 
From these observations, various point mutations were introduced to ClpP in an attempt to 
reveal the binding pocket, but no definitive conclusion was obtained.  
 
4.3 Sclerotiamide: The First Non-Peptide-Based Natural Product Activator of 
Bacterial Caseinolytic Protease P3 
4.3.1 Abstract 
Caseinolytic protease P (ClpP) maintains essential roles in bacterial homeostasis. 
As such, both the inhibition and activation of this enzyme result in bactericidal activity, 
                                                 
3 Reprinted with permission from: Nathan P. Lavey, Jesse A. Coker, Eliza A. Ruben, and Adam S. Duerfeldt, 
“Sclerotiamide: The First Non-Peptide-Based Natural Product Activator of Bacterial Caseinolytic Protease 
P” Journal of Natural Products 2016 79 (4), 1193-1197 DOI: 10.1021/acs.jnatprod.5b0109. Copyright 2016 
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making ClpP a promising target for antibacterial drug development. Herein, we report the 
results of a fluorescence-based screen of ∼450 structurally diverse fungal and bacterial 
secondary metabolites. Sclerotiamide (1), a paraherquamide-related indolinone, was 
identified as the first non-peptide-based natural product activator of ClpP. Structure-
activity relationships arising from the initial screen, preliminary biochemical evaluation of 
1, and rationale for the exploitation of this chemotype to develop novel ClpP activators are 
presented. 
4.3.2 Results 
While ClpP modulation has attracted serious interest from the antibacterial research 
community, little has been done to identify new ClpP modulating chemotypes. In fact, no 
natural product screen for ClpP modulators had been reported when our lab entered this 
space.28 In efforts to expand the arsenal of ClpP activating chemotypes, we screened a 
focused but structurally diverse subset of secondary fungal and bacterial metabolites, 
housed within our Institute for Natural Products Applications and Research Technologies 
(INPART). The complete library has been established by the Cichewicz laboratory over 
nearly a decade and is comprised of metabolites isolated from > 180 soil samples and > 80 
distinct zip codes across the United States.29 This continually growing collection includes 
a rich source of structural diversity (depsipeptides, alkaloids, carbocycles, terpenes, 
                                                 
American Chemical Society. N.P.L. conducted primary screen assays, secondary hit confirmation, and SDS-
PAGE degradation assays. J.A.C. equally contributed to primary screen assays, secondary hit confirmation, 
and data analysis. E.A.R. helped with initial protein purification. N.P.L. and A.S.D. designed the research 
studies, analyzed and interpreted the data, and wrote and reviewed the manuscript.  
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polyketides, non-ribosomal peptides, etc.) and biological activity, which has provided leads 
in a number of targeted phenotypic screens and functional assays.30–33 Thus, we believed 
this library represented a promising untapped source to screen for novel natural product 
ClpP activators. 
 
 
Figure 4.3 B-scored broad screen data and “hits” table 
(A) Raw FITC-β-casein degradation screening results. Threshold for analysis is indicated 
by the red line (ΔRFU ≥ 22,500). Inset: Enlarged area of threshold exceeding “hits”. (B) 
Fluorescence data, validation of initial “hits”, and structure of sclerotiamide (1). ΔRFU = 
change in relative fluorescence units, IF = intrinsic compound fluorescence, PA = inherent 
compound proteolytic activity, ND = not determined. 
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For the initial screen, a fluorescence-based protease assay that utilizes a 
commercially available internally quenched fluorogenic ClpP substrate, FITC-β-casein, 
was employed.26 Approximately 450 natural products were screened at a single 
concentration (50 µM) for the activation of recombinant E. coli ClpP (EcClpP). Enopeptin 
A34,35 (25 µM) and ACP526 (50 µM), a natural ADEP analog and a small molecule, 
respectively, were implemented as positive controls. In the presence of an activating 
molecule, ClpP-mediated cleavage of FITC-β-casein relieves internal quenching of the 
substrate and yields a fluorescent output of protease activity that can be quantified with a 
fluorimeter (excitation/emission: 485/538 nm). In the absence of an activating molecule, 
ClpP is unable to proteolyze FITC-β-casein and fluorescence remains quenched.  
As shown in Figure 4.3, a threshold of 22,500 raw ΔRFUs was set and any 
compound exhibiting an end-point fluorescence greater than this threshold was analyzed 
further.  In total, 11 hits were identified, two of which were the positive controls, Enopeptin 
A (A, Figure 4.3A) and ACP5 (B, 4.3A). The remaining nine hits were resubjected to the 
assay conditions to confirm the observed activity. All nine demonstrated reproducibility, 
which provided a respectable initial hit rate of 3.6%.  To eliminate false positives, hits were 
evaluated for both intrinsic fluorescence and inherent proteolytic activity, which 
disqualified eight of the nine hits (Figure 4.3B). However, when the raw screening data 
were replotted using the B-scoring algorithm,36,37 only a single true hit was detected. To 
measure intrinsic fluorescence, 538 nm emission was measured after 485 nm excitation for 
each compound (50 µM) in assay buffer. To measure inherent proteolytic activity, hit 
compounds (50 µM) were incubated with FITC-β-casein (192 µM) in assay buffer and 
fluorescence readings were taken to evaluate time dependent inherent proteolytic 
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properties. As such, sclerotiamide (1, Figure 4.3B),38 a paraherquamide related indole 
alkaloid natural product, was the only hit to pass both validation filters and B-score 
analysis, and was evaluated further. 
 
Figure 4.4 Dose dependent EcClpP activation by ACP5, and 1 
(A) substrate = Abz-DFAPKMALVPYNO2 (B) substrate = FITC-β-casein (normalized to 
DMSO baseline fluorescence). 
 
Sclerotiamide was subjected to dose-dependent peptide (Abz-
DFAPKMALVPYNO2)22,39 and protein (FITC-β-casein) degradation analysis.  As shown in 
Figure 4.4, the potency of 1 parallels that of ACP5 and exhibits an apparent activation 
constant (Kapp) of 39.6 ± 4.9 µM for decapeptide degradation and 87.5 ± 5.0 µM for FITC-
β-casein degradation. It is worth noting that the consistent potency of ACP5 in these two 
assays differs from the trend observed for 1 and ADEP1, which also shows an increase 
(~10-fold) in Kapp from decapeptide to FITC-β-casein degradation (Table 4.1). Hill Plot 
analysis of 1 demonstrates modest positive cooperativity for ClpP binding (Hill coefficient: 
>1.5), suggesting an ADEP-like binding process. Although the potency is modest, 
especially in comparison to ADEP1 (FITC-β-casein, Kapp = 1.6 ± 0.4 µM, Hill coefficient: 
2.0), 1 is the first non-peptide based natural product ClpP activator discovered and thus 
   
 
 120 
provides unique chemical space to evaluate for SAR studies. As a member of the 
paraherquamide family, 1 possesses a 3-dimensional bicyclo[2.2.2]diazaoctane motif that 
has garnered significant attention from the synthetic community,40,41 and has recently been 
reported in closely related compounds that exhibit a range of biological activities.42,43 
  EC50 (µM) 
Compound DFAP FITC-Casein Hill slope 
ADEP1 0.1 ± 0.02 1.2 ± 0.1 1.6/1.5 
ACP5 25.4 ± 3.6 22.2 ± 2.3 1.4/1.4 
1 39.6 ± 4.9 87.5 ± 5.0 2.6/1.9 
Table 4.1 Dose-Response comparison of ADEP1, ACP5, and 1 for the Decapeptide 
(DFAPKMALVPYNO2) and unstructured protein (FITC-β-Casein) substrates. 
 
 
Figure 4.5 SDS-PAGE degradation of β-casein by ClpP in the presence of 1  
SDS-PAGE analysis of ClpP homologue-dependent degradation of unlabeled β-casein by 
1 (50 μM) in comparison to ADEP1 (1 μM). 
 
Further validation of EcClpP activation by 1 was confirmed by SDS-PAGE 
analysis (Figure 4.5), which demonstrates dose and time dependent activation of EcClpP 
and subsequent degradation of unlabeled β-casein. Interestingly, when 1 was evaluated for 
its propensity to activate B. subtilis ClpP (BsClpP), no significant activation was observed 
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(Figure 4.5). This lack of BsClpP activation was noted in both fluorescence-based 
degradation assays and SDS-page analysis. To our knowledge, this is the first example of 
a ClpP activator that demonstrates a noticeable selectivity between bacterial homologs and 
we are currently probing the utility of this observation.  
 
Figure 4.6 Initial paraherquamides structure-activity-relationships  
(A) Additional paraherquamide related compounds present in the initial FITC-β-casein 
degradation screen (B) Relative ClpP activation of 1 and related compounds. 
 
Upon reinvestigation of the screened compound set, we noted that six additional 
members of this family were included within the screen (2–7, Figure 4.6A). Interestingly, 
however, all six of these analogs fail to elicit ClpP activation to any significant extent 
(Figure 4.6B). Most notable from this group is notoamide B (2), which only lacks the C-
10 α-oriented secondary hydroxyl group.44 This lack of activity by 2 identifies the C-10 α-
hydroxy motif as a necessary fixture in this natural product class for ClpP activation. In 
A B 
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addition, the 3-dimensional attributes imparted by the spiroindolinone moiety seem to be 
important, as all other congeners exhibit a fused architecture and fail to activate ClpP. 
Indicative of its relatively modest apparent binding affinity, 1 failed to inhibit the 
growth (> 100 µM) of permeabilized and efflux pump deficient E. coli M5418 (ΔacrB, 
ΔacrD, ΔacrEF::spc ΔemrB ΔemrY ΔentS::cam ΔmacB ΔmdtC ΔmdtF)45 and 
Pseudomonas aeruginosa PAO1116 ((ΔmexAB-oprM), (ΔmexCD-oprJ), (ΔmexEF-oprN), 
(ΔmexJK), (ΔmexXY), and (ΔtriABC))46 proprietary strains. These results suggest that 
although 1 is capable of activating recombinant EcClpP, improvement of potency is 
required for cellular target engagement and efficacy. Molecular dissection to identify the 
pharmacophore for this class of ClpP-activating natural products and X-ray 
cocrystallization studies are currently ongoing in our laboratory. Results from these studies 
will be communicated in due course and will contribute to structure-guided approaches 
aimed at improving upon the ClpP activation potency of this chemotype. Furthermore, the 
process outlined here will be expanded upon to enable the screening of natural product 
extracts, allowing for the interrogation of much larger chemical diversity. 
 
4.4 Discussion 
Overall, the utility of ClpP activation and inhibition has been established. To 
exploit ClpP as a target clinically, however, new chemical scaffolds are required. 
Leveraging our affiliation with the Institute of Natural Products Applications and Research 
Technologies (INPART) at the University of Oklahoma, we conducted the first reported 
natural products screen for new ClpP activators and identified the first non-peptide-based 
ClpP activator, sclerotiamide. While this compound lacks potency and fails to exhibit 
   
 
 123 
antibacterial activity at the concentrations tested, it provides a new scaffold for medicinal 
chemistry interrogation. Future studies are planned to synthesize new lead analogs, and 
attempts to gain structural information are ongoing. 
 
4.5 In Brief: Consequences of Depsipeptide Substitution on the ClpP Activation 
Activity of Antibacterial Acyldepsipeptides4 
4.5.1 Abstract 
The acyldepsipeptide (ADEP) antibiotics operate through a clinically unexploited 
mechanism of action and thus have attracted attention from several antibacterial 
development groups. The ADEP scaffold is synthetically tractable, and deep-seated 
modifications have produced extremely potent antibacterial leads against Gram-positive 
pathogens. Although newly identified ADEP analogs demonstrate remarkable antibacterial 
activity against bacterial isolates and in mouse models of bacterial infections, stability 
issues pertaining to the depsipeptide core remain. To date, no study has been reported on 
the natural ADEP scaffold that evaluates the sole importance of the macrocyclic linkage 
on target engagement, molecular conformation, and bioactivity. To address this gap in 
                                                 
4 Yangxiong Li, Nathan P. Lavey, Jesse A. Coker, Jessica E. Knobbe, Dat C. Truong, Hongtao Yu, Yu-Shan 
Lin, Susan L. Nimmo, and Adam S. Duerfeldt. “Consequences of Depsipeptide Substitution on the ClpP 
Activation Activity of Antibacterial Acyldepsipeptides” ACS Medicinal Chemistry Letters 2017 8 (11), 
1171-1176DOI: 10.1021/acsmedchemlett.7b00320. Copyright 2017 American Chemical Society. N.P.L. 
conducted the bioactivity analysis. N.P.L. and A.S.D. designed the research studies, analyzed and interpreted 
the data, and wrote and reviewed the manuscript.  
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ADEP structure–activity relationships, we synthesized three ADEP analogs that only differ 
in the linkage motif (i.e., ester, amide, and N-methyl amide) and provide a side-by-side 
comparison of conformational behavior and biological activity. We demonstrate that while 
replacement of the naturally occurring ester linkage with a secondary amide maintains in 
vitro biochemical activity, this simple substitution results in a significant drop in whole-
cell activity. This study provides direct evidence that ester to amide linkage substitution is 
unlikely to provide a reasonable solution for ADEP instability. 
4.5.2 Results 
In addition to screening for new chemotypes, we have also attempted to address 
liabilities of the highly potent yet relatively unstable ADEPs. Unfortunately, we discovered 
that simply altering the depsipeptide linkage with a more stable amide linkage abolishes 
activity against bacteria, even though target-engagement seems undisturbed. We believe 
that this is attributed to a disruption of an intramolecular hydrogen bond, which is known 
to enhance molecular rigidity, a feature shown to be crucial for permeation of cyclic 
peptides and depsipeptides. 
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Figure 4.7 A) ADEP analogs synthesized and evaluated in this study. (B) Target 
fragments for the convergent synthesis of 1-3.  
 
Specifically, hydrolysis of the ADEP depsipeptide ester under basic or acidic 
conditions has been a major concern regarding this natural product family.20,47 In fact, 
recent studies report near total degradation of various ADEPs in Mueller–Hinton broth 
within 24 h; a surprising claim given the benign nature of this broth.47 A common approach 
to improve the stability of ester linkages is to simply replace the ester with an amide or N-
methyl amide. Ester to amide substitution has demonstrated utility to improve not only 
stability, but also to decrease off-target cytotoxicity and enhance permeability of cyclic 
lipodepsipeptides.48,49 While ester to amide substitution has been investigated sporadically 
on ADEP analogs,50,51 no direct systematic comparison of compounds differing in only the 
macrocyclic linkage type (i.e., −O–, −NH–, −NMe−) has been reported. Furthermore, all 
linkage substitutions reported to date have been conducted on “pre-rigidified” ADEP 
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analogs, in which unnatural amino acids have been introduced into the macrocyclic core to 
enhance structural rigidity.50,51 Incorporation of unnatural rigidification in addition to 
macrocyclic linkage substitution imparts a multivariable effect, which may introduce 
conflicting conformational strains and make it difficult to delineate the specific effect of 
linkage substitution. As such, to determine the sole effect of the linker on the naturally 
occurring ADEP macrocyclic core, we have synthesized three ADEP analogs that differ 
only in the linkage type and have evaluated these analogs to provide insight regarding 
target engagement, molecular conformation, permeation, and antibacterial activity (Figure 
4.7). 
4.5.3 Bioactivity Evaluation 
Similar to the natural cochaperones, ADEP binding results in the reorganization of 
ClpP and a subsequent widening of the proteolytic chamber.52,53 Upon chemoactivation of 
ClpP, however, proteolysis is hyper-activated and unregulated and thus detrimental to 
bacterial survival. To biochemically compare the ClpP activation potential of each analog, 
we evaluated the ability of 1–3 to induce degradation of a self-quenching decapeptide 
(Abz-DFAPKMALVPYNO2).23 ClpP-induced cleavage of the decapeptide between the 
aminobenzoic acid fluorophore (Abz) and 2-nitrotyrosine quencher releases fluorescence, 
which can be quantified with a fluorimeter. Compounds 1–3 were evaluated over an 11-
point dose range to determine an apparent binding constant (Kapp) for ClpP activation. As 
shown in Table 1, the order of potency is 1 > 2> 3, with a ∼two-fold difference in potency 
between 1 and 2 and an additional ∼50-fold drop between compounds 2 and 3. This 
demonstrates a significant SAR for the ADEP cyclic peptide linkage on ClpP activation 
potency. However, it also suggests that substitution may be allowable, as a respectable 
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level of activity is maintained, especially when comparing the ester (1) with the secondary 
amide (2) linkage. All three analogs exhibit a Hill Slope coefficient >1, suggesting modest 
positive cooperativity in ClpP binding, a phenomenon indicative of ClpP activators that 
bind competitively to the cochaperone IGF loop binding pocket.14 As shown in Table 4.2, 
the ester linked ADEP (1) exhibits an improved stabilization of ClpP in melt experiments 
relative to both the −NH– (2) and −NMe– (3) compounds. This result is in agreement with 
the Kapp values determined in the decapeptide degradation assay. 
Compound Kapp (μM) 
H/D exchange  
t1/2 (min)a ΔTm (°C) MIC (μM:μg/mL)c 
1 (−O−) 0.037 ± 0.005 38 29.1 0.037:0.027 
2 (−NH−) 0.085 ± 0.01 <4b 22.8 6.25:4.6 
3 (−NMe−) 4.39 ± 0.60 <4b 12.7 >25:>18.6 
Table 4.2 Activity comparison between ADEP analogs.  
aAmide hydrogen of the alanine residue within the cyclic peptidolactone/peptidolactam 
core at 40 C in CD3OD.  
bExchange was complete prior to the first scan.  
cB. subtilis (ATCC 6051). 
 
All three compounds were evaluated in broth microdilution minimum inhibitory 
concentration (MIC) assays against B. subtilis. As shown in Table 4.2, the ester exhibited 
the greatest whole-cell activity (37 nM) followed by the amide (6.25 μM) and then the N-
methyl amide (>25 μM). Therefore, while the biochemical activity and thermal 
stabilization studies suggest −NH– macrocyclic substitution to be commensurate with the 
natural depsipeptide (∼two-fold difference), the whole-cell activity demonstrates a 
significant difference in efficacy (>150-fold difference), presumably due to a decrease in 
the efficiency of membrane permeation.54,55 
   
 
 128 
Inspection of the published ADEP1·ClpP (PDB ID: 3KTI) and ADEP2·ClpP (PDB 
ID: 3KTK) cocrystal structures reveals that the oxygen comprising the ester linkage of the 
depsipeptide is not involved in either intramolecular or intermolecular interactions when 
bound to ClpP.20,53 As such, we hypothesized that any observed differences in biological 
activity, especially between the −O– and −NH– linkages likely arises from conformational 
differences. To evaluate the effect of linkage substitution on the conformational dynamics 
of the cyclic peptidolactone/peptidolactam cores, we conducted hydrogen–deuterium 
exchange experiments. Specifically of interest were the H/D exchange properties of the 
alanine residue within the cyclic peptidolactone/peptidolactam cores. Intramolecular 
hydrogen bonding of the alanine −NH– and the extracyclic 3,5-difluorophenylalanine 
carbonyl is observed in ADEP·ClpP cocrystal structures and thus has been postulated as 
an important feature in ADEP binding.20,23 Strengthening this intramolecular hydrogen 
bond interaction can be accomplished by incorporation of a pipecolate residue in the 
depsipeptide core.23 This structural modification leads to more rigidified analogs that 
mimic the bound conformation and thus reduces entropic binding penalties, resulting in the 
observed improvement in potency for rigidified ADEPs.23 
The −O-linked compound (1) exhibited a much longer H/D exchange rate (t1/2 = 38 
min) than the −NH– (2) and −NMe– (3) compounds, both of which revealed complete H/D 
exchange within the time required to setup the experiment (t1/2 < 4 min). This suggests that 
both the −NH− and −NMe− linkages perturb the macrocyclic conformation enough to 
disrupt the important intramolecular hydrogen bonding interaction between the alanine 
−NH− and the carbonyl of the 3,5-difluorophenylalanine. This is noteworthy in regards to 
the whole-cell activity, as intramolecular hydrogen bonding of macrocycles has been 
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shown to enhance permeation through lipid bilayers, presumably by decreasing energetic 
penalties for desolvation of hydrogen bond donors, especially NH groups.54,55 Thus, 
although the overall effect of macrocyclic conformation for −O– to −NH– substitution in 
the linker is relatively small and can be easily overcome in the biochemical assay, it is 
plausible that the disruption of this intramolecular hydrogen bond negatively affects 
permeation and contributes significantly to the decreased whole-cell activity of 2. 
Not surprisingly, the −NMe– linkage results in more drastic deviations from the optimal 
macrocyclic conformation, disrupting the intramolecular hydrogen bonding and likely 
producing a large amount of cis amide conformer. This cannot easily be overcome during 
binding, thus resulting in significant decreases in both potency and whole-cell activity. 
Indeed, our NMR analysis strongly indicates a conformational mixture of multiple highly 
populated conformations for 3. 
4.5.4 Conclusion 
In summary, we have synthesized and biochemically evaluated three ADEP 
analogs that only differ in the type of linkage (i.e., −O–, −NH–, and −NMe−). This 
systematic study allowed for the direct comparison of linkage substitution on target 
engagement, conformation, and whole-cell activity. In biochemical activity assays, the −O-
linked analog (1) exhibits ∼two-fold and ∼100-fold better potency than the −NH– (2) and 
−NMe– (3) analogs, respectively. In MIC experiments against B. subtilis, 1 is ∼170-fold 
and >650-fold more active than 2 and 3, respectively. In all biochemical assays in which 
these derivatives were evaluated, this 1 > 2 > 3 trend of activity was observed. 
Computational and spectroscopic analyses revealed that conformation is likely the key 
factor in differentiating target engagement and whole-cell activity. We demonstrate that 
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simple replacement of the naturally occurring ester linkage with a secondary amide may 
not severely compromise the in vitro biochemical activity (target engagement), but results 
in a significant drop in whole-cell activity, presumably due to a disruption of a key 
hydrogen bonding interaction that is critical to cell permeation. As such, the excellent 
potency exhibited by rigidified ADEPs may not only arise from the preorganization of the 
depsipeptide core into a conformation optimized for ClpP binding, but also from an 
enhanced permeation profile. This study provides direct evidence that ester to amide 
linkage substitution is unlikely to yield a solution to ADEP instability and further highlights 
the need to continue the exploration for new ClpP activating chemotypes. 
 
4.6 Materials and Methods 
4.6.1 General Experimental Procedures  
Positive controls were purchased from commercial sources and include enopeptin 
A (Santa Cruz Biotechnology, #sc-397311A), ADEP1 (Cayman Chemical, #15305), and 
ACP5 (Chembridge #5107473). ClpP substrates were purchased from commercial vendors 
and include FITC-β-casein (Sigma-Aldrich, C3777, 20−50 μg FITC per mg solid) and Abz-
DFAPKMALVPYNO2 (Biomatik). Fluorescence readings were recorded on an i-TECAN 
Infinite M200 plate reader. Gel images were acquired on a Bio-Rad ChemiDoc MP CCD 
imaging system. All data analyses were performed with GraphPad Prism. 
4.6.2 Protein Purification  
Two different E. coli cell strains were used for overexpression. EcClpP was 
overexpressed in BLR (DE3) from Novagen and BsClpP in BL21 (DE3) from New 
England Biolabs. Overexpression and purification conditions for both proteins were 
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similar. Cell strains transformed with the relevant plasmids were grown at 37 °C to an 
OD600 of 0.7 followed by induction with 1 mM isopropyl β-D-thiogalactopyranoside and 
overnight overexpression at 25 °C. Cell pellets were resuspended in 20 mM Tris and 150 
mM NaCl (pH 8.0) and lysed using an Avestin C3 Emulsiflex. Lysates were clarified by 
centrifugation at 12 000 rpm for 30 min and incubated with Ni-NTA (Qiagen) resin pre-
equilibrated with 20 mM Tris and 150 mM NaCl (pH 8.0). Protein was eluted from Ni-
NTA resin with 20 mM Tris, 150 mM NaCl, and 500 mM imidazole (pH 8.0) and 
concentrated. Gel filtration, using a Superdex 200 Increase size exclusion column (GE 
Healthcare), was used as a final purification step for both proteins. Gel filtration buffer 
conditions were 25 mM Tris, 100 mM KCl, and 10% glycerol (pH 7.5)56 for EcClpP and 
25 mM HEPES, 100 mM KCl, 20 mM MgCl2, 1 mM EDTA, and 10% glycerol (pH 7.6)57 
for BsClpP. Protein concentrations were determined using the calculated molar extinction 
coefficient in 6 M guanidinium hydrochloride.58 
4.6.3 FITC-Casein Screening Assay  
300 nM tetradecameric EcClpP in buffer A (25 mM Tris-HCl, pH 7.5, and 100 mM 
KCl) was incubated with compounds (50 µM) at 37 °C for 15 minutes in flat bottom, non-
binding, non-sterile, white polystyrene 96-well plates (Corning 3990). After the pre-
incubation period, 1 µL of a 19.2 mM FITC-β-casein solution (Sigma-Aldrich, C3777, 20-
50 µg FITC per mg solid) in buffer A, was added to each assay well to give a final assay 
concentration of 192 µM FITC-β-casein and final assay volume of 100 µL. Assay plates 
were incubated at 37 °C and hydrolysis of the fluorogenic peptide was monitored via a 
TECAN Infinite M200 plate reader (excitation: 485 nm; emission: 538 nm). Readings were 
taken every 30 minutes for 6 hours. All compounds, along with Enopeptin A (25 µM, 
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positive control) and 1% DMSO (negative control) were normalized relative to background 
FITC-β-casein fluorescence. Data analysis was executed with GraphPad Prism. 
4.6.4 Decapeptide Degradation Assay  
As described previously,22 25 nM tetradecameric EcClpP in buffer B (25 mM 
HEPES, pH 7.5, 100 mM KCl, 5 mM MgCl2, 10% glycerol, and 1 mM DTT) was incubated 
with the compound of interest over a range of concentrations at 30 °C for 15 minutes in 
flat bottom, non-binding, non-sterile, white polystyrene 96-well plate (Corning 3990). 
After the pre-incubation period 1µL of a 1.5 mM Abz-DFAPKMALVPYNO2 (Biomatik) 
solution was added to each assay well to give a final assay concentration of 15 µM 
fluorogenic decapeptide and final assay volume of 100 µL. Assay plates were incubated at 
30 °C and hydrolysis of the fluorogenic peptide was monitored via an TECAN Infinite 
M200 plate reader (excitation: 320 nm; emission: 420 nm). Readings were taken every 30 
minutes for 2 hours. All compounds, along with ADEP1 (positive control) and 1% DMSO 
(negative control) were normalized relative to background Abz-DFAPKMALVPYNO2 
fluorescence. Data analysis was executed with GraphPad Prism. 
4.6.5 FITC-Casein Degradation Assay  
257 nM tetradecameric EcClpP in buffer A (25 mM Tris-HCl, pH 7.5, and 100 mM 
KCl) was incubated with the compound of interest over a range of concentrations at 37 °C 
for 15 minutes in flat bottom, non-binding, non-sterile, white polystyrene 96-well plate 
(Corning 3990). After the pre-incubation period 1 µL of a 0.45 mM FITC-β-casein (Sigma-
Aldrich, C3777, 20-50 µg FITC per mg solid) solution in buffer A was added to each assay 
well to give a final assay concentration of 4.5 µM fluorogenic decapeptide and final assay 
volume of 100 µL. Assay plates were incubated at 37 °C and hydrolysis of the fluorogenic 
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peptide was monitored via an TECAN Infinite M200 plate reader (excitation: 485 nm; 
emission: 538 nm). Readings were taken every 30 minutes for 6 hours. All compounds, 
along with ADEP1 (positive control) and 1% DMSO (negative control) were normalized 
relative to background FITC-β-casein fluorescence. Data analysis was executed with 
GraphPad Prism.  
4.6.6 SDS-PAGE Analysis  
420 nM tetradecameric EcClpP or BsClpP in buffer A (59 µL) was incubated with 
the compound of interest at the desired concentration for 15 minutes at 37 °C in Eppendorf 
tubes. 16 µL of a bovine β-casein (Sigma-Aldrich C6905, Bio-Ultra ≥ 98%) solution in 
buffer A was then added for a final substrate concentration of 7.5 µM and a final assay 
volume of 75 µL. The reaction was quenched with 25 µL of Laemmli loading buffer (Alfa 
Aesar J60015) at 80 °C. Individual reactions were quenched after 5 m, 30 m, 1 h, and/or 2 
h depending on the compound. The samples were then boiled for approximately 1 minute 
prior to loading. Time-dependent degradation of the β-casein band visualized using SDS-
PAGE performed on a 10% acrylamide Bis-Tris gel. 
4.5.7 MIC Determination  
Using the 2-fold dilution technique in 96-well microtiter plates, cells were 
subcultured (1:100 dilution) in fresh LB media (tryptone 10 g/L, yeast extract 5 g/L, and 
NaCl 5 g/L) and grown to an OD600 of ∼1.0. Cells were inoculated at a density of 105 
cells per mL into LB media in the presence of 2-fold increasing concentrations of 1. MIC 
values were determined visually after incubation of the microtiter plates at 37 °C for 18 h. 
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4.6.8 Thermal Shift Assay  
All compounds were evaluated at a final assay concentration of 50 µM. 1 µM 
BsClpP monomer (71.4 nM tetradecamer) and 2 µL of 5 mM compound of interest 
prepared in activity buffer 2 (20 mM HEPES pH = 7.0, 100 mM NaCl) in 1.5 mL Eppendorf 
tubes. SYPRO baseline control and DMSO negative control were prepared similarly. 
Protein and controls were pre-incubated for 30 min at 25 °C. After pre-incubation, 2 µL of 
100X SYPRO Orange Protein Gel Stain, prepared in 100% DMSO and stored in light-free 
desiccator at 25 °C, was added to the samples and mixed thoroughly for a total volume of 
200 µL. The large 200 µL samples were split into 3 x 50 µL wells in 96-well, Hard Shell®, 
thin-wall PCR Plates (BioRad HSP9601) sealed with optically clear Microseal® ‘B’ 
adhesive seals (BioRad MSB1001). The resulting plates were spun in a tabletop PCR plate 
spinner (VWR 89184-608) in 15 sec intervals until all bubbles were removed. Samples 
rested in the dark for 10 min and were then evaluated using BioRad CFX96 TM Real-Time 
System. Melt curves were prepared in increments of 0.3 °C per minute over a range of 25 
°C to 85 °C, with FRET readings taken after a 1-minute hold at each temperature. Melting 
temperatures were determined by nonlinear fitting to a Boltzmann Sigmoidal Curve using 
GraphPad Prism. 
4.6.9 MIC Determination  
B. subtilis ATCC 6051 was streaked onto an LB agar plate and grown overnight at 
37 °C. Pre-warmed (37 °C) Mueller–Hinton broth (5 mL) was inoculated with 3–5 colonies 
of B. subtilis. The culture was incubated at 37 °C shaking at 250 rpm overnight. The 
resulting overnight stock solution of B. subtilis was diluted 1:100 to provide the assay stock 
solution. Following standard microdilution protocol1 compounds 1–3 were serially diluted 
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to provide a final well volume of 200 µL. Briefly, 2 µL of compound stock was added to 
198 µL of Mueller-Hinton broth. This was then serially diluted 2-fold down the plate by 
taking 100 µL and transferring to the subsequent well that contained 100 µL of Mueller–
Hinton broth. To each well was then added 100 µL of the 1:100 dilution B. subtilis assay 
culture to obtain a final well volume of 200 µL. Plates were incubated overnight at 37 °C 
and after 16 h, MIC values were determined by visual inspection. Reported MIC values 
indicate the concentration of the last well containing no visible cell growth. Ampicillin and 
Kanamycin were used as positive controls. DMSO treatment was used as a negative 
control. Buffer only wells were included as a control/indicator of bacterial contamination. 
Each compound was tested in triplicate. Top concentrations for each compound evaluated: 
Ampicillin (125 µg/mL, 357.7 µM), Kanamycin (125 µg/mL, 258.0 µM), 1 (0.183 µg/mL, 
250 nM). 2 (18.25 µg/mL, 25 µM), 3 (18.60 µg/mL, 25 µM). Stock solutions for each 
compound evaluated: Ampicillin (71.5 mM), Kanamycin (51.6 mM), 1 (50 µM), 2 (5 mM), 
and 3 (5 mM).  
4.6.10 Hydrogen-Deuterium Exchange  
Purified ADEPs 1 and 2 were stored in a desiccator for one week at 25 °C prior to 
H/D exchange experiments. The NMR probe was pre-equilibrated to either 25 °C or 40 °C 
before introduction of the NMR sample. NMR samples were prepared by dissolving 
compound 1 or 2 in ampule sealed CD3OD at a concentration of 2 mM. The samples were 
mixed and promptly transferred to a clean NMR tube. 1H-NMR spectra were acquired at 
500 MHz with 8 scans, 1 second delay, sweep width of 8012.8 Hz and 16384 complex 
points. Timing of each kinetic run was carefully started upon sample mixing. The time of 
the first collected spectra was designated as t1. Subsequent spectra were collected at 300 
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second intervals with a 24 second acquisition time. The kinetic runs were terminated when 
the amide peaks were completely exchanged and no longer visible. The data was processed 
in MestReNova software. The data was zero filled to 65536 points with a 0.70 Hz 
exponential function and baseline correction applied upon processing. The integration of 
the exchanging amide signal of interest was calibrated to a non-exchanging reference peak 
and converted to concentration. The concentration versus time data was analyzed using 
PRISM software.  
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Chapter 5  
The Crystallographic Structure of Caseinolytic Protease P1 from 
Clostridium difficile 6305 
5.1 Abstract 
 We sought to determine the structure of each caseinolytic protease P (ClpP) isoform 
in Clostridium difficile to provide structural evidence to better understand why ClpP1 is 
susceptible to acyldepsipeptide activation, while ClpP2 was not. Furthermore, the 
structural information obtained would allow us to tailor chemical modulators to each 
isoform. Our efforts resulted in producing crystals of each isoform, eventually yielding the 
crystallographic structure of ClpP1 at 2.5Å resolution. Herein, the crystallization and 
structural solution of ClpP1 will be discussed. 
  
                                                 
5 N.P.L. conducted the crystallization, collected the datasets, and provided initial structural solutions. Leonard 
Thomas from the Macromolecular Core Laboratory provided the final refined structural solution, and 
validated the ClpP1 structure for Protein Database submission. All datasets were collected at the Stanford 
Synchrotron Radiation Lightsource. 
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5.2 Results 
Broad screen crystallization trials were performed in order to find suitable 
crystallization conditions that would yield large, high quality crystals of each ClpP isoform 
(Appendix C). ClpP1 was overexpressed in JK10 cells and purified as described in Chapter 
2. Sitting drop crystallization experiments were conducted with ClpP1 at a concentration 
of 4.5 mg/mL, aliquoted into 96-well plates in 1:1 or 2:1 to crystallization buffer. ClpP1 
readily crystallized in several different conditions at room temperature, with 2.6M sodium 
malonate at pH 7.0 providing large crystals in a relatively short period of time (<4 days). 
We chose sodium malonate as our primary condition to optimize because sodium malonate 
is an excellent cryoprotectant, making this step much easier in the future.1 To optimize this 
condition, we performed hanging drop crystallization experiments in 24-well plates over a 
range of sodium malonate concentrations, and varying pH. 2.4M sodium malonate at pH 
6.0 yielded the largest crystals in approximately 2 days, and this was routinely reproduced 
successfully. These crystals were then screened for diffraction at the Macromolecular Core 
Laboratory (MCL) before being sent to the Stanford Synchrotron Radiation Lightsource 
(SSRL). 
The ClpP1 crystals provided diffraction patterns of sufficient quality which were 
processed in HKL2000 for scaling and merging. These datasets were then processed in 
PHENIX  with Molecular Replacement (MR) to provide the initial structural solution.2 The 
individual datasets lacked sufficient completeness (>95%), requiring two datasets in the P1 
space group to be combined with BLEND.3,4 After the datasets were combined, scaled, and 
merged, the structural solution via MR yielded the structure of ClpP1 in the active extended 
conformation (Figure 5.1). 
   
 
 146 
 
Figure 5.5 - Structure of ClpP1 in the Active Extended Conformation 
The structure of ClpP1 in the active extended conformation was solved via MR, and further 
refined in PHENIX before deposition in the Protein Database (PDB) under 6MX2. The 
biological unit is shown above in the side pose (left) and the top pose (right). The data 
collection and refinement statistics are listed in Appendix C.2.   
 
The structure of ClpP1 from C. difficile possessed no obvious differences from 
other known structures of ClpP listed in the PDB. This was anticipated as the structure of 
ClpP is highly conserved, even when compared to other isoforms with low sequence 
similarity. By itself, the structure of ClpP1 is not particularly useful nor impactful to report 
within the field. The structure serves to confirm our initial results in Chapter 2, in that 
ClpP1 forms a stable tetradecameric complex that is not contaminated with E. coli ClpP. 
 
5.3 Future Directions 
 Our future directions are immediately concerned with obtaining the crystal 
structure of ClpP2 in the active extended conformation. Currently, we are able to produce 
crystals of ClpP2 in several different conditions that successfully diffract. Unfortunately, 
these datasets severely lack completeness and are poor in quality. Optimizing our initial 
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crystallization conditions will aid in obtaining higher quality datasets for ClpP2, and these 
experiments are currently underway. As stated initially, obtaining a crystallographic 
structure of ClpP2 will provide the structural evidence for why ClpP1 and ClpP2 differ in 
susceptibility to ADEPs and aid in structure guided optimization of future chemical 
modulators. 
 
5.4 Materials and Methods 
5.4.1 Protein Production and Purification 
 ClpP1 and ClpP2 were overexpressed and purified as described in Chapter 2 of this 
dissertation, and were similarly kept in activity buffer for crystallization. We found that 
transferring to a simple crystallization buffer (50mM Tris pH 7.6, 100mM NaCl, 10% 
glycerol) triggered rapid precipitation of the protein. 
5.4.2 Crystallization and Structure Solution 
 ClpP1 and ClpP2 were each subjected to several commercial broad screen 
crystallization kits in a 96-well format at room temperature (Appendix C.1). Prior to any 
crystallization experiment, the protein was spun at 12,000 rcf for 8 minutes to ensure any 
precipitated protein was pelleted and discarded. A Mosquito liquid handler was used to 
dispense aliquots of ClpP1 and ClpP2 at 4.5 mg/mL into 96-well plates for sitting drop 
crystallization in 1:1 and 2:1 ratio against precipitation buffers, to a total volume of 300 
nL. Plates were then sealed with optically clear tape and allowed to crystallize at room 
temperature. Optimization of broad screen hits were formed in hanging drop experiments 
on silicon wafers, which were sealed with vacuum grease above wells in a 24-well plate. 
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Each well contained 500 L of precipitation buffer to which hanging drops were mixed 
with in 1:1, 2:1, and 1:3 ratios.  
 For ClpP1, crystals formed after 1-2d at room temperature in 2.6M sodium 
malonate at pH 6.0. These crystals were sufficiently cryoprotected, but sometimes were 
further cryoprotected by addition 3.2M sodium malonate at pH 6.0 directly to the hanging 
drop. Crystals were flash frozen in liquid N2 and shipped to the SSRL beamline 9-2 for 
remote data collection. These datasets were initially processed in HKL3000 for integration, 
merging, and scaling. The resulting dataset was then processed in PHENIX with MR to 
solve the structure against 3KTH. Phenix.refine was then used to refine the resulting 
structure, after manual refinement and residue correction via COOT. A final round of 
refinement was performed by PDB-REDO before submitting to the MCL for final structure 
refinement and validation.  
 
5.5 References 
1. Holyoak, T. et al. Malonate: a versatile cryoprotectant and stabilizing solution for salt-
grown macromolecular crystals. Acta Crystallogr. Sect. D, Biol. Crystallogr. 59, 2356–
2358 (2003). 
2. Adams, P. D. et al. PHENIX: a comprehensive Python-based system for 
macromolecular structure solution. Acta Crystallogr. Sect. D, Biol. Crystallogr. 66, 
213–221 (2010). 
3. Mylona, A. et al. A Novel Approach to Data Collection for Difficult Structures: Data 
Management for Large Numbers of Crystals with the BLEND Software. Crystals 7, 242 
(2017). 
   
 
 149 
4. Winn, M. D. et al. Overview of the CCP4 suite and current developments. Acta 
Crystallogr. Sect. D, Biol. Crystallogr. 67, 235–242 (2011). 
  
   
 
 150 
 
  
   
 
 151 
Epilogue 
This body of work biochemically and phenotypically describes the ClpP system in 
C. difficile. Our long-term goal for this project was to show the biological significance of 
targeting ClpP, in order to introduce ClpP as a new target against CDI. To do so, we wanted 
to directly address the current challenges facing the development of therapeutics for 
treating CDI. We first set out to understand what the operative ClpP system was before we 
moved into the pathogen itself. This included understanding how each ClpP isoform 
assembled, how they behaved in vitro, and what the structures were. We accomplished this 
initial goal, both biochemically and structurally characterizing the ClpP system in C. 
difficile. Those results laid the groundwork for pursuing the biological significance of the 
ClpP system in C. difficile 630.  
Future experiments will build upon the work described throughout this dissertation 
that will be concentrated on sporulation, virulence, and nutrient response regulation. Our 
immediate attention will be focused towards completing the work described in Chapter 3, 
as many of these studies are currently underway. The most critical gaps are: 1) generating 
complements for clpP1, clpP2, and clpP1P2, 2) quantifying sporulation regulatory factor 
transcripts via qRTPCR in clpP mutants, and 3) obtaining spo0A mutants as our sporulation 
negative control. The complements will be necessary in order to show that loss of ClpP 
function is responsible for the asporogenic phenotype, and not a consequence of our 
mutagenesis.  
Broader future directions related to the work described in this dissertation are: 1) 
Replicating the asporogenic phenotype in C. difficile through chemo-modulation of ClpP, 
and 2) completing RNAseq in clpP mutants to globally monitor sporulation regulatory 
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signals after loss of ClpP function. ClpP inhibitors already exist which have not yet been 
assayed for activity against either ClpP1 or ClpP2. In order to assess ClpP inhibition as a 
viable therapeutic strategy to combat CDI, in vitro activity assays are planned to determine 
whether known ClpP inhibitors are active against C. difficile ClpP isoforms. More broad-
spectrum inhibitors such as phenylmethylsulfonyl fluoride are commercially available and 
broadly inhibit serine proteases which could be used in the event ClpP inhibitors are 
ineffective. RNAseq experiments are currently being planned which will help define the 
role each ClpP isoform maintains in regulating sporulation. For example, ClpP1 and ClpP2 
maintain specific roles in processing the engulfment machinery protein SpoIIP. RNAseq 
would help to differentiate ClpP1 from ClpP2 by understanding the overarching regulation 
of sporulation which may contribute to the processing of SpoIIP which would be highly 
impactful to C. difficile sporulation research as SpoIIP processing is currently not 
understood.  
Advancing our understanding of these fundamental processes critical to sporulation 
may reveal new therapeutic targets that are more tractable, or easier to target. Results from 
these studies could eventually aid in the design of new chemical probes and antibiotics to 
better understand sporulation and translate into real therapeutics to combat the transmission 
and spread of CDI. 
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Appendix A: Sequences and supporting data for Clostridium difficile 
ClpP Homologs are Capable of Uncoupled Activity and Exhibit 
Different Levels of Susceptibility to Acyldepsipeptide Modulation 
 
Primer ID Primer Sequence (5’-3’) 
rpoB_F AACTAGGGCCAGAGGAAATAAC 
rpoB_R CTGAGTCTACTTCTGCACCTATTC 
clpP1_F GCTGAAGACCCAGACAAAGATA 
clpP1_R CTCCCATAGAAGCAGCCATAC 
clpP2_F GGCTCTGCTACATCAGGATTTG 
clpP2_R CATGTGTTCCTCCTGCAAGTAA 
Table A.1 qRTPCR Primers.  
Integrated DNA Technologies (IDT) PrimerQuest tool was used to pick primer pairs for 
clpP1 and clpP2. rpoB, the gene that encodes the β-subunit of bacterial RNA polymerase, 
was used as the reference gene.  
 
 
clpP1 clpP2 rpoB 
Log 14.80 ± 0.02 20.88 ± 0.02 16.81 ± 0.00 
Stationary 17.34 ± 0.01 22.68 ± 0.02 19.89 ± 0.02 
Table A.2 Ct counts for qRT-PCR Individual Ct values for each transcript quantified 
Raw Ct counts for qRT-PCR experiments performed in Chapter 2. 
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Figure A.1 HR-ESIMS peptide digest and sequencing results.  
Combined sequence coverage of ClpP1 (bottom) and ClpP2 (top) prepared from ΔEcClpP. 
Coverage obtained following data merging after trypsin and chymotrypsin digest. Bold 
underline: identified sequence; green: amino acids differing between the two isoforms.  
 
 
Figure A.2 pUNK DLS results for ClpP1 prepared from ΔEcClpP cells.  
DLS measurements were performed in order to demonstrate monodispersity of the ClpP1 
sample, and understand if multiple complexes were being performed. 
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Figure A.3 pUNK DLS results for ClpP2 prepared from ΔEcClpP cells. 
DLS measurements were performed in order to demonstrate monodispersity of the ClpP2 
sample, and understand if multiple complexes were being performed. 
 
 
Figure A.4 Predicted ClpP2 disulfides predicted by DiANNA. 
DiANNA webserver can predict potential disulfide bond interactions given the primary 
sequence of the protein of interest. This was performed in order to understand the potential 
for ClpP2 to form disulfide bonds which may have explained the lack of peptidolytic or 
proteolytic activity in our initial activity experiments. 
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Figure A.5 Reduction or oxidation of ClpP2 has no consequences on proteolytic 
activity.  
A) SLY-AMC peptidolytic assay over 2h, fluorescence measurements taken 30 m, 60 m, 
and 120 m with and without 5 mM DTT. B) SLY-AMC peptidolytic assay with reducing 
(DTT) and oxidizing (H2O2) conditions had no effect on proteolytic activity of ClpP2. 
Inset, Aliquots from GFP-ssrA degradation assays were diluted 10-fold into 100 µL activity 
buffer containing 5 mM DTT and pipetted in triplicate into a black 96-well flat bottom 
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plate. SLY-AMC was added, and the reaction was allowed to proceed for ~48h before 
reading.  
 
 
 
  
 
 
 
 
 
 
Figure A.6 Peptidolytic activity of mixed solutions of ClpP1 and ClpP2 compared to 
homogenous solutions.  
An attempt to assess whether or not ClpP1 and ClpP2 could form a heteromeric complex 
in vitro. When mixed in equal concentrations, the relative intensities generated by the 
mixture is approximately half of the relative intensity observed in ClpP1 alone. In this 
manner, it appears that ClpP1 is chiefly responsible for the majority of observed 
fluorescence. 
 
 
 
Rate of Degradation (ΔRFU, min^-1) 
 
 
SLY Rel. ClpP1 Z-GGL Rel. ClpP1 
ClpP1 1944 n/a 540.6 n/a 
ClpP2 21.1 1.1 8.0 1.5 
ClpP1 + ClpP2  899.8 46.3 306 56.6 
C
lp
P
1
C
lp
P
2
C
lp
P
1 
+ 
C
lp
P
2
0
2000
4000
6000
R
F
U
****
*
C
lp
P
1
C
lp
P
2
C
lp
P
1 
+ 
C
lp
P
2
0
10000
20000
30000
40000
R
F
U
****
SLY Z-GGL 
   
 
 158 
 
 
Figure A.7 Non-denaturing PAGE gel (7-15%) of mixed ClpP1 and ClpP2 
homotetradecamers after 2 h. 
As shown by native PAGE, mixing the two homogenous assemblies of tetradecameric ClpP 
was unable to produce a heteromeric complex.  
 
 
Lane Contents 
1 GoldBio BlueStain Protein Marker 
2 ssrA-GFP 
3 ssrA-GFP + ClpP 
4 ssrA-GFP, ClpP, ClpX, no ATP 5 h 
5 ssrA-GFP, ClpP, ClpX, + 4 mM ATP 1 h 
6 ssrA-GFP, ClpP, ClpX, + 4 mM ATP 2 h 
7 ssrA-GFP, ClpP, ClpX, + 4 mM ATP 3 h 
8 ssrA-GFP, ClpP, ClpX, + 4 mM ATP 4 h 
9 ssrA-GFP, ClpP, ClpX, + 4 mM ATP 5 h 
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Figure A.8 SDS-PAGE visualization of ssrA-GFP degradation over time via ClpXP 
in the presence of 4 mM ATP.  
Individual lane assignments are the same between both ClpP1 and ClpP2 SDS-PAGE gels, 
as listed in the table above.   
 
 
Figure A.9 Raw data replicates of ClpP1 + ADEP thermal shift experiments.  
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Figure A.10 Raw data replicates of ClpP2 + ADEP thermal shift experiments. 
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Appendix B: Phenotypic Response from the Loss of ClpP Function in 
Clostridium difficile 
 
 
Figure B.1 All C. difficile strains grown anaerobically in minimal defined media 
supplemented with glucose at 37 ºC and 42 ºC.  
Minimal defined media was used in order to assay potential differences in nutrient response 
regulation. Clear differences emerge under heat-shock conditions, where P1 and P2 
differ from the WT in significant ways. P1P2 appears to grow while P1 mutants appears 
to be unable to grow. This suggests that ClpP1 may function to directly or indirectly 
regulate a nutrient response regulator, while it is less obvious if ClpP2 plays an important 
role in regulation and nutrient response regulator.  
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Figure B.2 Motility assays were performed in 50% BHIS media (0.3% agar)  
Motility was not significantly reduced in any of the knockout mutants. Statistical 
significance was assessed via One-way RM ANOVA using Dunnet’s test to correct for 
multiple comparisons. 
 
 
Figure B.3 Bright field microscopy of elongated P1P2 cell phenotype  
harvested from BHIS cultures and immobilized on 1% agarose pads, observed via 100x 
oil-immersion under a Ph3 filter. White arrows denote apparent phase-bright spores. Scale 
bar represents 5 µm.  
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Figure B.4 TEM overview image of WT harvested from 70:30 plate media 
   
 
 164 
 
 
Figure B.5 TEM overview image of purified WT spores harvested from 70:30 plate 
media 
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Figure B.6 TEM overview image of P1 harvested from 70:30 plate media 
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Figure B.7 TEM overview image of purified P1 spores harvested from 70:30 plate 
media 
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Figure B.8 TEM overview image of P2 harvested from 70:30 plate media 
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Figure B.9 TEM overview image of purified P2 spores harvested from 70:30 plate 
media 
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Figure B.10 TEM overview image of P1P2 harvested from 70:30 plate media 
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Figure B.11 TEM overview image of purified P1P2 spores harvested from 70:30 
plate media 
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Figure B.12 Spore production is significantly lower in BHIS liquid media for all 
mutants with comparison to WT after 2 days 
Spores were enumerated with BHIS media + 0.1% taurocholate plate media post 70 ºC heat 
shock for 30 min. Plates were grown for at least 24h prior to colony counts. 
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Figure B.13 pMTL84151 plasmid map  
The plasmid map for pMTL84151 that was used to create clpP mutants using 
CRISPR/Cas9 mutagenesis. Each clpP1 and clpP2 were separately inserted into the lacZ 
operon along with 100 bp upstream from the clpP gene. The native expression of each ClpP 
isoform was used to complement the single mutants. 
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Appendix C: The Structure of ClpP1 from Clostridium difficile 
ClpP1 
Condition 
Time To 
Crystallize 
(days) Morphology 
0.1M Tris-base pH 8.5, 2.0M ammonium sulfate 2 small plates 
0.1M sodium acetate pH 4.5, 2.0M sodium chloride 4 needles 
0.1M Tris-base pH 8.5, 2.0M ammonium sulfate 2 small plates 
0.1M HEPES pH 7.5, 1.4M tri-sodium citrate 1 large plates/cubes 
0.1M HEPES pH 7.5, 1.4M tri-sodium citrate 1 large plates/cubes 
0.2M ammonium acetate, 0.1M Bis-tris pH 5.5, 45% v/v 
MPD >21 large plates/cubes 
0.2M ammonium acetate, 0.1M Bis-tris pH 6.5, 45% v/v 
MPD >28 large plates/cubes 
0.2M ammonium acetate, 0.1M Bis-tris pH 6.5, 45% v/v 
MPD >28 large plates/cubes 
0.2M lithium sulfate, 0.1M Tris-base pH 8.5, 25% w/v 
PEG 3350 >35 small plates 
0.16M MgCl2, 24% w/v PEG 4k, 0.08M Tris pH 8.5, 
20% w/v glycerol 4 small plates 
0.16M MgCl2, 24% w/v PEG 4k, 0.08M Tris pH 8.5, 
20% w/v glycerol 4 medium plates 
0.2M potassium sulfate, 20% w/v PEG 3350 8 small cubes 
2.0M ammonium sulfate 0.1M HEPES pH 7.5 1 small rectangular plates 
0.2M sodium formate pH 7.3, 20% w/v PEG 3350 14 small cubes 
0.2M lithium chloride, 20% w/v PEG 3350 14 small cubes 
60% v/v Tacsimate pH 7.0 >30 large plates/cubes 
0.2M sodium fluoride, 20% w/v PEG 3350 >21 small cubes 
1.4M di-ammonium tartrate, 0.1M Tris pH 8.5 1 large plates/cubes 
2.8M sodium acetate pH 7.0 1 small cubes 
0.2M lithium sulfate, 2.0M ammonium sulfate, 0.1M 
CAPS 1 small plates 
2.8M sodium acetate pH 7.0 1 small cubes 
0.2M lithium citrate, 20% w/v PEG 3350 1 small rectangular plates 
ClpP2 
0.1M HEPES pH 7.5, 1.4 tri-sodium citrate 1 small cubes 
2.1M Malic acid, pH 7.0 1 small plates 
2.4M sodium malonate, pH 7.0 1 small plates 
0.1M Bis-tris pH 6.5, 28% w/v PEG MME 2k >30 small plates 
0.1M HEPES pH 7.5, 25% w/v PEG 3350 >30 small plates 
0.2M ammonium sulfate, 0.1M Bis-tris pH 6.5, 25% w/v 
PEG 3350 >14 small plates 
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0.2M sodium chloride, 0.1M Tris-base pH 8.5, 25% w/v 
PEG 3350 10 small hexagonal plates 
0.2M lithium sulfate, 0.1M HEPES pH 7.5, 25% w/v 
PEG 3350 >21 small plates 
0.2M sodium formate, 20% w/v PEG 3350 >28 large cylinders 
0.1M potassium thiocyanate, 30% w/v PEG MME 2k >21 large rectangle 
0.15M potassium bromide, 30% w/v PEG MME 2k >37 large rectangle 
0.1M Bis-tris pH 6.5, 28% w/v PEG MME 2k >12 small cylinders 
0.1M Bis-tris pH 6.5, 25% PEG 3350 >28 small cylinders 
0.2M sodium thiocyanate pH 6.9, 20% w/v PEG 3350 >21 large cylinders 
0.2M MgCl2, 30% v/v PEG 400, 0.1M Tris pH 8.5 4 medium plates 
0.2M sodium thiocyanate pH 6.9, 20% w/v PEG 3350 >21 cylinders/plates/cubes 
0.2M potassium sulfate, 20% w/v PEG 3350 >28 small cubes 
2.4M sodium malonate pH 7.0 1 small cubes 
0.2M di-ammonium hydrogen citrate pH 5.0, 20% w/v 
PEG 3350 4 needles 
0.2M potassium iodide, 20% w/v PEG 3350 >28 medium cubes 
 
Table C.1 Crystallization conditions for ClpP1 and ClpP2 
Wavelength 0.98 Å 
Resolution range 34.06  - 2.498 (2.587  - 2.498) 
Space group P 1 
Unit cell 97.328 97.372 106.494 113.149 104.562 103.213 
Total reflections 460673 (45316) 
Unique reflections 109963 (10507) 
Multiplicity 4.2 (4.3) 
Completeness (%) 98.01 (94.19) 
Mean I/sigma(I) 5.46 (1.79) 
Wilson BFactor 27.6 
Rmerge 0.2181 (0.5619) 
Rmeas 0.2484 (0.6379) 
Rpim 0.1176 (0.2989) 
CC1/2 0.935 (0.715) 
CC* 0.983 (0.913) 
Reflections used in refinement 109922 (10505) 
Reflections used for RFree 5435 (523) 
RWork 0.1917 (0.2305) 
RFree 0.2436 (0.3085) 
CCWork 0.944 (0.849) 
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CCFree 0.925 (0.712) 
Number of non-hydrogen atoms 20431 
  macromolecules 19627 
  ligands 23 
  solvent 781 
Protein residues 2551 
RMS(bonds) 0.003 
RMS(angles) 0.48 
Ramachandran favored (%) 96.95 
Ramachandran allowed (%) 3.05 
Ramachandran outliers (%) 0 
Rotamer outliers (%) 0 
Clashscore 3.85 
Average B-factor (Å2) 30.54 
  macromolecules 30.54 
  ligands 29.25 
  solvent 30.56 
Table C.2 The data collection and refinement statistics for the crystal structure of 
ClpP1 
